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ABSTRACT

THE IMPACT OF STATIN USE ON OUTCOMES OF DIABETIC ADULT
PATIENTS HOSPITALIZED FOR COMMUNITY ACQUIRED PNEUMONIA

Joel Lanceta
November 19, 2021

BACKGROUND: Statins, a class of drugs that treat hyperlipidemia, may have an
immunosuppressive effect for patients with community acquired pneumonia
(CAP). Retrospective and in vitro studies have suggested an immunomodulatory,
antioxidative and anticoagulant effects from statin use in patients with Type 2
Diabetes Mellitus (T2DM) hospitalized for CAP. Prospective studies that have
tested any effect of statin therapy on patients with T2DM and CAP have not been
found literature. To date, prospective studies showing of the effects statin therapy
may have on T2DM patients hospitalized for CAP are not available.
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METHODS: This dissertation is a secondary analysis using deidentified data
collected from the HAPPI Study, a prospective CAP observational study conducted
in nine adult acute-care hospitals in Louisville, Kentucky, from 2014-2017. HAPPI
patients were grouped by T2DM, prior statin exposure, and age. Decision tree
analyses were performed to indicate how strongly the T2DM and statin interaction
is related to outcomes of mortality (after one, six, and 12 months) and CAP
rehospitalization (after one, six, and 12 months). Multivariate logistic regression
analyses were used to identify potential covariables. Propensity score matching
(PSM) and the McNemar test were used to compare the odds ratios of outcomes on
paired statin users (cases) and non-statin users (controls) based on age and T2DM.

RESULTS: From 10052 CAP patients, 1265 of 2734 T2DM patients were on
statins (46.3%) and 2340 of 7318 non-T2DM patients were on statins (32.0%). The
decision tree analysis, logistic regression analysis, and survival analysis indicated
that statin use in T2DM patients age < 65 years was significantly associated (OR =
0.55, p < 0.01) with a decreased likelihood for all-cause mortality at one, six, and
12 months. Analysis after PSM found statin use in T2DM patients age < 65 was
associated with non-significantly decreased odds for one, six, and 12 month
mortality (OR = 0.70, p = 0.09). The logistic regression analysis and PSM analysis
showed no significant difference in mortality likelihood between T2DM patients
age ≥ 65 with statin use and those without statin use. No significant difference was
seen in rehospitalization between T2DM cases and controls in either age groups.

v

CONCLUSIONS: Decision tree analysis, logistic regression analysis, and Cox
regression analysis showed that the T2DM and statin interaction was significantly
associated with decreased mortality at one, six, and 12 months for T2DM patients
age <65 , but not in T2DM patients age ≥ 65. A prospective case control study with
a larger sample size to account for PSM may validate these findings to be
significant. This dissertation emphasized the continued study of statin therapy for
the attenuation of CAP severity and improved outcomes.
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CHAPTER 1
INTRODUCTION
Background to the Study
From June 1, 2014 to March 31, 2016, the University of Louisville Division of
Infectious Diseases conducted the University of Louisville Pneumonia Hospitalized
Adults with Pneumococcal Pneumonia: Incidence (HAPPI) Study, a prospective
cohort study of all adults hospitalized for community acquired pneumonia (CAP).
The purpose of HAPPI was to define the incidence, epidemiology, and mortality of
CAP in Louisville, Kentucky. To the best of the author’s knowledge, HAPPI was
the first population-based study evaluating data on the number of unique patients
who required hospitalization after being diagnosed for CAP in the United States.1
One benefit from HAPPI was in collecting the diverse demographic and
medical history of its patient population, including the prevalence of comorbid
diseases in hospitalized CAP patients. This allows for a better illustration of how
two of the most common metabolic diseases in the United States, Type 2 Diabetes
Mellitus (T2DM) and dyslipidemia (DLP) affect the disease process of CAP.
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Type 2 Diabetes Mellitus (T2DM) and Metabolic Disorders
T2DM is a metabolic disorder primarily caused by insulin deficiency with or
without insulin resistance. Hyperglycemia associated with T2DM results in the
production of glycated metabolic end-products and reactive oxygen species,
impairing immunity and giving rise to proinflammatory conditions.2-4These
metabolic disturbances contribute to multiple downstream complications, such as
renal failure, retinopathy, neuropathy, and osteomyelitis. T2DM is associated with
worse outcomes in patients with coronary artery disease (CAD),5 chronic
obstructive pulmonary disease (COPD),6 and peripheral artery disease (PAD).7
Increased frequency of morbidity and mortality results from these complications.8
Overweight (OW) and obesity (OB) are two interconnected metabolic
disorders. The prevalence of OW and OB in the US population has been increasing
since the 1950s, with an estimated 73.6% of Americans age ≥ 20 years being OW
or OB.9 OW is defined as a calculated body mass index (BMI) of 25 to 29.9 kg/m2;
OB as a BMI of >30 kg/m2. The risk for impaired glucose tolerance is directly
proportional to increased body adipose tissue, specifically central (abdominal)
obesity. OB is a risk factor for the development of T2DM, as well. However, some
studies have described the “Obesity paradox”, a phenomenon which associates
lower mortality and improved prognosis, for obese patients with T2DM compared
to T2DM patients with normal weight in certain disease states, such as
pneumonia.9,10
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Dyslipidemia and Statin Therapy
DLP is a chronic condition with an abnormal elevated serum total cholesterol
(hyperlipidemia), elevated low-density lipoprotein (LDL) and triglycerides, and
decreased high-density lipoprotein (HDL). DLP is diagnosed clinically when
triglycerides are considered above 150 mg/dL, LDL is above 130 mg/dL and HDL
is below optimal levels at 60 mg/dL. Elevated blood cholesterol is associated with
increased age, gender, genetics, and other modifiable lifestyle factors such as diet,
exercise, tobacco smoking cessation, alcohol consumption, and BMI. DLP is
considered a major risk factor for the development of CAD. DLP is often treated in
primary and secondary prevention of cardiovascular events.11,12
A class of drugs known as statins are the mainstay of pharmacotherapeutic
treatments for DLP. Statins belong to a class of drugs that inhibit
hydroxymethylglutaryl coenzyme A reductase (HMG-CoA), the rate-limiting
enzyme in the metabolic pathway of cholesterol synthesis. Their actions cause
potent reductions in total cholesterol and LDL-lowering effects.11 Importantly for
this thesis, statins are known to affect major histocompatibility complex II receptors
(MHC II), which play a role in initiating immune responses.13

CAP (Community Acquired Pneumonia)
CAP is defined as an acute infection of lung parenchyma acquired outside of a
hospital or healthcare-based setting, or from other recent contact within the
healthcare system.1,14,15 Despite advances in antimicrobial therapy in the past 70
3

years, CAP remains the 7th leading cause of death in the United States overall, and
the most common infectious cause of death.16 Patients hospitalized for CAP are
also at increased odds for developing complications during hospitalizations,
including need for mechanical ventilation secondary to hypoxic respiratory failure,
possible shock requiring vasopressors, and multiorgan failure.1,17

Proposed Models of Interaction between T2DM, Statins, and CAP
Statins also have been shown to have immunomodulatory, antioxidative and
anticoagulant effects in CAP patients. Statins have been studied as a possible
adjunct therapy to improve the prognosis for CAP.18,19 T2DM is a risk factor for
cardiovascular disease, even in the absence of known CAD, thus the ADA
recommends statin therapy for the majority of patients with T2DM.20
Several aspects of immunity and inflammation are altered by T2DM. In T2DM
patients with poor glycemic control, CAP hospitalization has been associated with
higher morbidity and mortality.21-23 Impairment of leukocytes and phagocytosis
associated with T2DM,24,25 and proinflammatory cytokines and chemokine
induction through gene upregulation in monocytes also associated with T2DM may
play a role.26
Prospective studies that have tested any effect of statin therapy on patients with
T2DM and CAP have not been found literature. To date, prospective studies
showing of the effects statin therapy may have on T2DM patients hospitalized for
CAP are not available.
4

Problem Statement
The objective of this study is to analyze the impact of ongoing statin exposure
and their health outcomes of patients with T2DM hospitalized for CAP.

Research Aims
A. Mortality of CAP Patients with T2DM and Statin Therapy
Aim 1: Analyze whether or not all-cause mortality rates at 1 month, 6 months
or 12 months after CAP hospitalization, are different between statin-exposed
T2DM patients and statin-exposed non-T2DM patients, with statin non-exposed
T2DM and non-T2DM patients are the controls.
H0: Mortality rates at 1, 6, and 12 months after CAP hospitalization for statinusing T2DM patients (OR1) are not statistically different from statin-using nonT2DM and non-exposed statin T2DM patients (OR2).
H0: OR1= OR2
HA: Mortality rates at 1, 6, 12 months after CAP hospitalization for statinexposed T2DM patients is statistically significantly different from statin-using nonT2DM and non-exposed statin T2DM patients.
HA: OR1 ≠ OR2
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B. Morbidity of CAP Patients with T2DM and Statin Therapy
Aim 2: Analyze whether or not readmission rates for CAP at 1, 6 or 12 months
after the initial CAP hospitalization are different between statin-exposed T2DM
patients and statin-exposed non-T2DM patients, with statin non-exposed T2DM
and non-T2DM patients are the controls.
H0: Readmission for CAP at 1, 6 or 12 months after CAP hospitalization of
statin-using T2DM patients (OR1) is not statistically different from statin-using
non-T2DM and non-exposed statin T2DM patients (OR2).
H0: OR1 = OR2
HA: Readmission for CAP at 1 month, 6 months or 12 months after CAP
hospitalization of statin-using T2DM patients is statistically significantly different
from statin-using non-T2DM and non-exposed statin T2DM patients.
HA: OR1 ≠ OR2

Significance
Prior studies that analyzed the outcomes of statin therapy on patients with CAP
and T2DM were retrospective/historic cohort studies. This study will be one of the
first to use a prospective cohort design to analyze the effect of statin therapy on allcause mortality from discharge to one year after hospitalization in T2DM and nonT2DM patients requiring hospitalization for CAP.
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Additionally, rehospitalization for CAP up to one year after initial stay will be
analyzed in this study to determine whether or not T2DM or non-T2DM
populations should be targeted for a more aggressive treatment course to lower the
likelihood of rehospitalizations and decrease associated costs.

Summary
Retrospective

and

in

vitro

studies

have

suggested

an

anti-

inflammatory/protective effect of statin use in T2DM patients hospitalized for
CAP, however no prospective cohort study has been published to date.
The present investigation will be a secondary analysis of the prospectively
collected data from the University of Louisville HAPPI study to analyze whether
or not statin use affects mortality and morbidity outcomes in T2DM patients
hospitalized for CAP. The primary outcome is mortality after CAP hospitalization
and the secondary outcome is rehospitalization for CAP after the initial
hospitalization. A cost analysis of CAP rehospitalization will also be conducted in
the treatment and control groups.
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CHAPTER 2
LITERATURE REVIEW
Diabetes Mellitus and Related Metabolic Disorders
Insulin, one of the key main anabolic hormones of the human body, is a peptide
hormone that promotes glucose absorption, glyconeogenesis, lipogenesis, and
protein synthesis. After its release by the pancreas, insulin binds to its receptors on
hepatic, adipocytic and skeletal muscle cells, initiating a cascade of cellular
processes that promotes glycogen and fat synthesis from the absorbed glucose,
while inhibiting gluconeogenesis and glycogenolysis by the liver. 27-29
The current American Diabetes Association (ADA) guidelines no longer
diagnose Type 1 diabetes mellitus (T1DM) and T2DM based on the traditional
paradigm of age at onset because both diseases can occur in childhood and
adulthood. Instead, the ADA now defines T1DM as insulin deficiency due to
autoimmune antibody-mediated disease destruction of the pancreatic β-cells.30 By
comparison, T2DM is diagnosed by the progressive loss of insulin secreted by
pancreatic β-cells frequently associated with cellular insulin resistance, causing
hyperglycemia. Hyperglycemia associated with T2DM causes a proinflammatory
and prothrombotic reaction. Classic symptoms of T2DM include intense thirst,
increased urination, headache, blurred vision, poor wound healing, fatigue, and
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numbness or tingling in the extremities. T1DM may also present with clinical
symptoms similar to T2DM but with the added symptoms of weight loss and
increased hunger.31 Complications from untreated or poorly managed T2DM
include atherosclerotic cardiovascular disease,5 peripheral vascular disease,7,32
diabetic foot ulcers,33 chronic kidney disease,34-36 retinopathy,37 neuropathy,38 and
increased odds for respiratory infections (i.e CAP).39-41
Pathways associated with β-cell failure and dysfunction are less well defined
for T2DM than in T1DM. Genetic predisposition, environmental, metabolic, and
inflammatory stress, have contributed insulin resistance and T2DM onset. These
patients with metabolic, environmental, and genetic determinants for T2DM are
currently targeted for future clinical algorithms.42,43
Prediabetes (intermediate hyperglycemia) is associated with elevated serum
glucose below the diagnostic threshold of T2DM. Prediabetes patients may present
with the classic symptoms of hyperglycemia, and are at increased odds for OB,
dyslipidemia, and hypertension. Prediabetes often leads to T2DM due to
simultaneous insulin resistance, β-cell dysfunction, and other possible clinical
T2DM complications without meeting the official glycemic threshold for diagnosis.
Unlike T2DM, prediabetes may be reversible with dietary and lifestyle changes,
although an estimated 5-10% of patients with prediabetes will progress to T2DM.4446

Metabolic syndrome, also known as Syndrome X, refers to a cluster of cooccurring clinical conditions that include central (abdominal) OB, hyperglycemia,
hypertriglyceridemia, and hypertension. Like T2DM, metabolic syndrome causes a
9

proinflammatory

and

prothrombotic

state

characterized

by

upregulated

inflammatory cytokine production and activity. Patients with OB and metabolic
syndrome have a six-to-ten-fold increased odds for developing CAD, T2DM, and
stroke compared to obese patients without metabolic syndrome.47,48
T2DM, metabolic syndrome and prediabetes are closely related due to their
overlapping clinical and pathophysiological presentation, although how their
pathways intersect is still to be defined by medical research.

T2DM, Prediabetes, and Metabolic Syndrome Diagnosis
ADA screening and diagnosing criteria for T2DM differs between patients with
symptomatic hyperglycemia and those with asymptomatic hyperglycemia. Patients
presenting with classical hyperglycemia symptoms (i.e., thirst, polyuria, weight
loss, and blurry vision) may be diagnosed with T2DM with a non-fasting blood
glucose level of ≥ 200 mg/dL (11.1 mmol/L).
The diagnosis of T2DM in an asymptomatic patient is established with any of
the following laboratory test criteria:
•

Fasting plasma glucose of ≥126 mg/dL (7.0 mmol/L), with fasting is defined as no
caloric intake for at least eight hours.

•

Two-hour plasma glucose values of ≥200 mg/dL (11.1 mmol/L) during a 75 g oral
glucose tolerance test.

•

Hemoglobin A1C (HbA1c) value ≥6.5 percent (48 mmol/mol).
10

In asymptomatic patients, if only one test is available then the diagnosis of
T2DM warrants confirmation on a subsequent day with a repeated measurement. If
two of the test measures are available and concordant for a positive T2DM
diagnosis, then no additional testing is needed.30
Prediabetes screening identifies patients at high risk for the development of
T2DM. These patients present with impaired glucose tolerance, high fasting
glucose and HbA1c, but not at the threshold sufficient for T2DM. Prediabetes is
screened for and diagnosed using the same laboratory tests as for T2DM. Diagnosis
of prediabetes requires one of the following criteria to be positive:
•

Fasting plasma glucose between 100 and 125 mg/dL (5.6 to 6.9 mmol/L).

•

Two-hour plasma glucose value during a 75 g oral glucose tolerance test between
140 and 199 mg/dL (7.8 to 11.0 mmol/L).

•

HbA1c between 5.7 to <6.5% (39 to 48 mmol/mol).
If one of the diagnostic tests is consistent with prediabetes, then annual
screening with repeated testing is warranted.30
Metabolic syndrome does not have uniform diagnostic criteria described by any
major medical organization.49 Current practice makes the diagnosis of metabolic
syndrome based on the presence of any three of the five following findings:

•

Fasting blood glucose ≥ 100 mg/dL.

•

Blood pressure ≥130/85 mmHg.

•

Waist circumference of ≥102 cm (40 in) in males or ≥88 cm (35 in) in females.
11

•

Triglycerides ≥150 mg/dL.

•

High density lipoprotein cholesterol <40 mg/dL in males or <50 mg/dL in females.

Mechanisms of Inflammatory Cellular Damage in T2DM
Diabetics are more susceptible to infectious disease through two main
pathways: (1) impairment of the immune response,50 and (2) activation of
proinflammatory cytokines.51 How T2DM triggers the inflammatory process is still
under investigation. The current accepted model links inflammation and T2DM
through the activation of the c-Jun NH(2)-terminal kinase (JNK) and the inhibitor
of κappa-B kinase (IKK). Insulin resistance and the release of many chemokines
(cytokines of chronic inflammation), including interleukin (IL)-6, IL-10, and tumor
necrosis factor alpha (TNF-α).52,53 The role of inflammation as a common mediator
is linked to both the pathogenesis of T2DM and of OB.

54

Adipocytes (fat cells)

also secrete proinflammatory factors correlated with insulin resistance, including
leptin and adiponectin.55 T2DM incidence and its complications are correlated with
increased levels of inflammatory biomarkers, including C-reactive protein (CRP),
IL-6, plasminogen activator inhibitor 1 (PAI-1),56 TNF-α,

57

and white blood cell

count.58,59 Intensive lifestyle interventions aimed at T2DM glycemic maintenance
are known to decrease markers of inflammation.60
T2DM-related cellular level pathophysiology includes hyperglycemia
triggering the overproduction and release of reactive oxygen species as byproducts
of mitochondrial oxidative phosphorylation, contributing to cellular damage.61
12

Glucose also binds to multiple proteins through glycation, causing irreparable
alteration to protein structures and function. These byproducts contribute to the
accumulation of glycated proteins in diabetic microvascular diseases.62-64

Epidemiology and Costs of T2DM in the United States
Using self-reported data, the prevalence of U.S. adults aged 18 years or older
with diagnosed diabetes was between 26.8-34.2 million cases in 2018, with an
estimated 7.3 million undiagnosed diabetics.65,66 Of the diagnosed cases, 5.8% were
T1DM, 90.9% were T2DM, and 3.3% had mixed/hybrid type diabetes. Notably,
self-report data are believed to underestimate the actual number of adults in the
U.S. with diabetes. The incidence in the U.S. in 2020 was estimated to be 1.5
million new cases of diabetes, or 6.9 out of 1,000 persons. The number of T2DM
cases are expedited to increase precipitously in the next decade because of an
increase in T2DM diagnosis in youths and adolescents 10-19 years of age,
paralleling an increase in adolescent obesity.66-69
In 2017, the ADA estimated the total economic burden for diagnosed diabetes
was $327 billion in 2017, including $237 billion in direct healthcare costs, $71
billion in hospital inpatient costs and $90 billion in reduced productivity associated
with diabetic complications. People with diagnosed diabetes, on average, incur
medical expenditures of $9600 per year attributed to diabetes alone, approximately
2.3 times higher than expenditures incurred by non- diabetics. 70,71
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Dyslipidemia in the United States
In the U.S., approximately 94 million adults ≥ 20 years old in 2018 had total
cholesterol levels higher than 200 mg/dL, which is considered borderline elevated.
Over 28 million adults had total cholesterol levels ≥ 240 mg/dL, which is the cutoff
for dyslipidemia diagnosis.
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Dyslipidemia is a general term for the elevation of

any form of cholesterol, including triglycerides (hypertriglyceridemia), total
cholesterol (hypercholesterolemia) and low-density lipoprotein cholesterol. (LDLC). LDL-C is one of the five major groups of protein molecules that transport
cholesterol. It transfers lipid and cholesterol in extracellular fluid, making it
bioavailable to cells for receptor-mediated endocytosis. LDL-C is a known risk
factor for the development of atherosclerotic cardiovascular disease (ASCVD).
LDL-C accumulates in vasculature, causing vessel plaques that contribute to
atherosclerosis. LDL-C also contains many oxidative reactive species that can
contribute to the weaking of the cardiovascular vessels. High LDL-C indicates a
high risk of atherosclerosis and serves as an estimate of the total cholesterol load.73

Statin Therapy for Dyslipidemia
Treatment for dyslipidemia includes lifestyle and diet modifications, and drug
therapy

that

decreases

cholesterol

synthesis

and/or

absorption.

Hydroxymethylglutaryl (HMG) CoA reductase inhibitors (statins) belong to a class
of drugs given for lipid altering and reduction. Statins act as competitive inhibitors
for HMG CoA- reductase, an enzyme involved in the rate-limiting step of
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cholesterol biosynthesis. Statins also reduce very low-density lipoprotein (VLDL)
production via an effect mediated by hepatic apolipoprotein B secretion. Patients
with an LDL-C of >100 mg/dL (2.59 mmol/L) and a greater risk of ASCVD are
usually started on initial statin therapy.
In 2021, more than 35 million Americans are on statin therapy.
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T2DM is

considered a risk factor for ASCVD, with most patients screened for lipid
dysfunction at initial T2DM diagnosis. Among diabetic patients, statin therapy is
initiated based on ASCVD risk rather than LDL-C baseline levels. Thus, statins are
often given to diabetics even if LDL-C levels are lower than 100 mg/dL. 20

Statin-mediated Anti-Inflammatory Effects
In addition to cholesterol synthesis inhibition, statins have anti-inflammatory
and antioxidant effects in animal models and human. In vitro studies show that
statins reduce the release of proinflammatory factors, suppress the induction of
MHC-II molecules, and normally lead the inflammatory response to invasive
infections.13,75-77 Moreover, statins modulate and downregulate inflammatory
intracellular pathways involving kinase phosphorylation and protein prenylation. 78
Statins have a proven effect to reduce inflammation in patients with various
diseases such as CAD, chronic renal disease, and T2DM. Their pleiotropic effects
downregulate inflammation, and are known to significantly reduce markers of
inflammation (e.g., CRP, TNF, IL-6) Normolipidemic patients suppress the
transcription factor NF-κB, which controls a number of genes associated with
15

inflammation.79-81 Statins increase nitric oxide bioavailability, which helps maintain
endothelium homeostasis through anti-atherogenic effects.81 Statin therapy
upregulates gene expression of cellular antioxidant agents, suppress free radical
oxygen species, and decrease thrombosis by inhibiting platelet activation and
aggregation.82,83

Pneumonia Presentation and Pathophysiology
Pneumonias are defined by the location of infection acquisition. CAP is an acute
infection of the lung parenchyma acquired outside a hospital or healthcare facility
(i.e. rehabilitation center, hemodialysis center). Nosocomial pneumonias are
pneumonias acquired through healthcare settings and can be subdivided between
hospital-acquired (HAP) or ventilation-associated (VAP).
The clinical presentation of CAP can vary extensively. The most common
presentations are a combination of lower respiratory symptoms (i.e. cough,
productive sputum production, pleurisy, dyspnea,) with systemic infection
symptoms (i.e. fever >37.8°C, leukocytosis, fatigue, malaise, chest pain) that are
confirmed with radiological findings consistent with CAP. Computerized
topography of the chest is the gold standard in imaging, although for convenience,
cost savings, and speed, chest x-rays are usually performed first. On chest
radiographs, accumulation of white blood cells and fluid within the alveoli visually
appear as pulmonary opacities.84
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Bacterial pathogens, such as Streptococcus pneumoniae, Staphylococcus
aureus, Legionella , and Haemophilus influenza, and respiratory viruses are the
most frequently detected microbial pathogens in CAP patients. However, an
estimated 62-75% of hospitalized CAP cases do not identify the causative pathogen
despite extensive microbial testing.85,86
Although S. pneumoniae is the most commonly detected bacterial pathogen in
CAP, incidence of pneumococcal pneumonia has decreased in the U.S. since the
late 20th century to approximately 10-15% of CAP cases annually, in part due to
widespread pneumococcal vaccination of persons ≥ 65 years old.87 Subsequently,
increased recognition of CAP with high severity has occurred due to respiratory
viruses, such as influenza, parainfluenza, and respiratory syncytial viruses. A novel
variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), named
COVD-19 by the World Health Organization, is currently the most commonly
detected pathogen of CAP in the U.S. since 2020, occurring four years after the
close of the HAPPI study.
The pathogenesis of CAP begins with the aspirated or inhaled pathogen entering
the lower respiratory tract and begins multiplication in the lung alveoli, competing
with the normal respiratory flora. Detection of the pathogen by alveolar
macrophages releases cytokines that initiates a host immune response that can cause
inflammation and damage in the lung parenchyma. Progression into pneumonia is
dependent on multiple factors, such as the inoculum of the pathogen, virulence of
the pathogen, and frequency of aspirate.88 Conditions that impair the immune host
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response, such as chronic malnutrition, alcoholism, and T2DM, can increase the
severity of the developing pneumonia.

CAP Epidemiology and Health Determinants in the United States
Prior to the COVID-19 pandemic, the initial HAPPI study found that 650 adults
per 100,000 population in the U.S. were hospitalized for CAP annually,
corresponding to more than 1.5 million unique hospitalization to CAP yearly.89 The
true incidence of CAP may be underreported as patients with mild infections may
not seek medical attention.
The risk for CAP increases with patient age and chronic comorbidities. The
annual incidence of CAP among adults ≥ 65 years old is approximately 2000 per
100,000 in the U.S., and adults ≥ 65 years old are threefold more likely to be
hospitalized for CAP than the general population.1,90 Chronic medical
comorbidities that are associated with increased odds for CAP hospitalization
include chronic obstructive pulmonary disease (COPD) and other chronic lung
diseases (i.e. asthma, bronchiectasis), chronic heart failure, chronic kidney disease,
T2DM, epilepsy, stroke, and immunocompromised conditions. Lifestyle-related
factors, such as smoking, alcoholism, and chronic malnutrition are positively
correlated with increased incidence of CAP hospitalization. Socioeconomic factors
associated with an increased odds of CAP have included crowded living conditions
(i.e. prisons, homeless shelters), residence in low-income neighborhoods, and
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exposure to environmental toxins (e.g. nitrogen dioxide, sulfur dioxide,
gasoline).91-93
Despite advances in antimicrobial therapy, CAP still remains a leading cause of
hospitalization and mortality worldwide, particularly in the developing world. In
2015, CAP was the leading infectious cause of death, and the eighth leading cause
of death in the U.S.94 30-day mortality rates vary with pneumonia severity. The
CAP 30-day mortality rate was estimated to be 10%, and up to 20-25% in patients
with severe CAP.95,96 Respiratory complications and cardiovascular events (i.e.
myocardial infarctions, atrial fibrillation) occur frequently among patients
hospitalized for CAP, increasing the risk for mortality.97
CAP is associated with increased long-term mortality, although the range and
time to mortality is still unclear. 98,99 The HAPPI study followed CAP patients up
to one year after their initial CAP hospitalization and estimated that mortality was
23% at six months after hospitalization, and 31% at one year after hospitalization.
Extrapolating this mortality rate to the total number of estimated patients
hospitalized for CAP in the study year (1,581,860), the number of cumulative
deaths in the U.S. population would be estimated at 370,156 at six months after
CAP hospitalization, and 484,050 at one year after CAP hospitalization.1
30-day readmission for CAP have been estimated to be between 7 – 18% in the
U.S. Risk of recurrent and/or exacerbation of CAP increases with comorbidities,
such as the ones discussed above with increased odds for CAP hospitalization, and
increased age. 100,101
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CAP Healthcare Utilization and Cost Burden
Americans age ≥ 65 years have higher CAP incidence rates, higher rates of
hospitalization and higher mortality rates associated with CAP than any other age
group in the U.S.71 The average cost per pneumonia episode was US $10,962.5
($10,822.8-$11,102.2) for hospitalization from 2008 to 2014 (adjusted for inflation
in 2020 to be $11,896.8-12,204). The highest average pneumonia-related
healthcare utilization expenditure was for adults ≥ 65 year, who had an estimated
economic burden and total costs of $846.7 per 100,000 person-years from CAPrelated hospitalizations in 2015.70

Inflammatory Response of CAP and T2DM
T2DM increases the risk for infection and is an important and known risk factor
for CAP hospitalization and mortality.21,102,103 Hyperglycemia above ≥250 mg/dl is
a criteria on the Pneumonia Severity Index (PSI) that increases the likelihood of
severe pneumonia in the clinical management for the patient. In studies monitoring
glycemic control in T2DM patients, poor glycemic control (HbA1c ≥11%) was
associated with an increased odds for CAP compared to optimal glycemic control
(HbA1c 6–7%). 104
Mechanisms by which hyperglycemia increases the risk for CAP and its
severity were discussed above. T2DM alters chemotaxis, phagocytosis and
cytokine secretion in cell-mediated immunity, restricting the host’s ability to attack
the pathogen. This in turns increases CAP severity.24,105 Natural killer immune
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cells, which are effector lymphocytes that kill infected cells, have reduced activity
in T2DM. 106
The proinflammatory state caused by T2DM can lead to an exaggerated
response to pathogens by macrophages, monocytes, and T-cells in the lung. This
leads to the overproduction of proinflammatory cytokines (the so-called “cytokine
storm”) that may eventually damage the lung parenchyma.107,108 Additionally,
T2DM is associated with alveolar impairment, resulting in permeability of the
respiratory vasculature and reduced gas exchange, which may be aggravated in
CAP.109 Finally, endothelial dysfunction, commonly seen in microvascular disease
of T2DM, heightens pulmonary ischemia and tissue edema in CAP.110
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Statin Therapy in Patients with CAP and T2DM
Statins have known pleotropic effects in reducing reactive oxygen species and
regulating anti-inflammatory and antioxidant processes. Statins have long been
proposed as therapeutic agents in infectious diseases, such as influenza virus,
psoriasis, and more recently, COVID-19.111-113 Postulated beneficial effects of
statins specific to CAP patients include a reduced influx of inflammatory cells in
the lungs, prevention of T-cell activation, and improved neutrophil function,
including reduction of inflammatory markers and proinflammatory cytokines as
discussed above.114,115
The interaction between statins and T2DM is complex. Large randomized
clinical trials (RCT) have shown that statins may be diabetogenic, and that the risk
is slightly greater with intensive statin therapy than moderate statin therapy.116,117
The excess risk of developing T2DM from high dose statin therapy has been
estimated to be 50-100 cases per 10,000 treated individuals. The T2DM risk was
associated with other high-risk factors for T2DM, including elevated body mass
index (BMI), impaired fasting glucose, and high HbA1c.118 The pathogenesis of
T2DM by statins is currently unknown. Hypotheses include a causal relationship
between LDL receptor-mediated transmembrane cholesterol transport upregulated
by statins and T2DM, and the inhibition of the mevalonate pathway by statins
promotes adipose insulin resistance.119,120 In spite of this risk, statins are still
indicated for the treatment of T2DM given evidence from RCTs such as the
JUPITER trial, which found that statins reduce ASCVD events and mortality of
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patients with T2DM.121 Risk benefit analysis found that the benefit of statins is 50
times greater than the risk of T2DM.117
Several epidemiological studies have associated statin use with the reduced risk
of CAP severity in the general population, and in patients with T2DM. Many
retrospective studies have found more favorable short-term mortality and clinical
outcomes for CAP patients with T2DM on statin therapy compared to those not on
statins. Hypothetically, these benefits are a result of statins’ anti-inflammatory
effects.122-126
Among these studies are Douglas et al. (2011), that used propensity scores to
match every patient starting a statin between 1995 and 2006 in the United Kingdom
Health Improvement Network database to as many as five non-statin patients. The
patients were screened for diagnosis of pneumonia in their electronic medical
records and then subsequent all-cause mortality within six months of diagnosis. The
study estimated that within the six-month period, 13% of statin users died compared
with 19.7% of non-users, giving an adjusted hazard ratio of 0.67 (0.49 to 0.91)122
Mortensen et al. (2012) analyzed Department of Veterans Affairs (VA) data of
elderly patients hospitalized with CAP between 2002-2007 and used propensity
score matching to examine the association of statins, angiotensin converting
enzyme inhibitors (ACE-I) and angiotensin-receptor blockers (ARB) on CAPoutcomes. Statins were significantly associated with a decreased 30-day mortality,
decreased need for mechanical ventilation, and reduced length of stay in CAP
patients.123
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By comparison to Mortensen, Havers et al. (2016) was a prospective
observational study which used propensity score analysis to match statin users and
non-statin users among 2016 patients hospitalized for CAP in five non-VA
hospitals in Chicago, Illinois and Nashville, Tennessee. Havers et al. (2016) found
no significant association of statin use with decreased length of stay or in-house
mortality. However, they did not follow up with patient outcomes after
discharge.127
van de Garde et al. (2011) employed a matched case-control design, using ICD9 diagnosis data and medication lists from the UK Department of Health database,
to identify to CAP patients with diabetes and prior statin use. It matched one statintreated case with four controls matched on age, gender and date of diagnosis, while
co-morbidities such as cardiovascular and pulmonary diseases were controlled in
the regression. van de Garde et al. found statin use reduced the risk of fatal and nonfatal cases of CAP. However, it followed patients for 10 years beginning from 1987,
with a lower incidence of statin and a longer follow up period than the HAPPI
study.125
Policardo et al. (2017) is a retrospective case-control, a model similar to van de
Garde et al. (2011), using coded diagnoses and prescription filled lists of patients
in the Tuscany, Italy health system. Policardo et al. (2017) matched one statintreated case with two controls matched on age, gender and date of diagnosis, and
found statin use decreased the risk for CAP hospitalization in subjects without or
with diabetes.124
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One recent observational study conducted at a single hospital in Bronx, New
York compared outcomes for patients admitted for COVID-19 pneumonia,
grouping them as those who did and those who did not receive prior statin therapy.
Analysis after propensity score matching showed a significantly lower risk of inhouse mortality for COVID-19 patients with T2DM who received statins compared
to those who did not receive statins.128
Figure 2.1 displays the current known interactions between T2DM, CAP, and
statin therapy.
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Figure 2.1 Interactions between T2DM, CAP, and Statin Therapy
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Gaps in the Literature
Most publications that report a positive effect of statins on CAP are
retrospective observational studies with limited power. Meta-analyses aggregating
RCTs that included statins among other CAP interventions or nonrandomized
controlled studies were also based on retrospective data. These studies had
conflicting results in the analysis of length of statin treatment and the magnitude of
a preventative effect on CAP outcomes.129-133 Additionally, RCTs did not show the
positive effects of statins on outcomes that preclinical and observational studies
found.134 Only one ongoing RCT in the U.S. is evaluating statins with other
pharmaceutical interventions in critically ill patients with CAP.135 A prior RCT
found no effect of simvastatin therapy on the 28 day mortality of pneumonia
27

patients, but patients were diagnosed with VAP.136 To the best of our knowledge,
no large scale prospective cohort study showed the effect of statin therapy on the
long-term mortality and morbidity of T2DM patients hospitalized for CAP.
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CHAPTER 3
METHODS

Study Design
This present investigation is a secondary analysis of deidentified data
collected from the HAPPI Study, a prospective cohort study. The HAPPI Study
was conducted in nine adult acute-care hospitals in Louisville, Kentucky over
three years, from 6/1/2014-5/31/2016 and from 10/1/2016-3/31/2017. The author
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worked on HAPPI as a PhD student and research coordinator from 2014-2016.
A patient was deemed eligible for HAPPI by the following criteria met:
1) Presence of a new pulmonary infiltrate on chest radiograph and/or chest
computed tomography scan at the time of hospitalization, defined by a boardcertified radiologist’s reading,
2) At least one of the following symptoms of laboratory findings:
a) new cough or increased cough or sputum production;
b) Fever >37.8°C (100.0°F) or hypothermia <35.6°C (96.0°F);
c) Changes in leukocyte count;
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3) No alternative diagnosis at the time of hospital discharge that justified the
presence of criteria 1 and 2.
Patients admitted for CAP were deemed ineligible for enrollment in HAPPI if
they did not have a permanent or valid address in the Louisville, Kentucky area
based on the US Census Bureau data, did not possess a valid Social Security
Number (SSN), or were incarcerated in a corrections system or mental health
facility at the time of hospital admission.
Past medical history and medication treatment was verified using electronic
medical records (EMR) and diagnostic coding (ICD-9 from 6/1/2014- 10/14/2015,
ICD-10 after 10/15/2015).
All the data was deidentified prior to analysis, using an industry standard
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deidentification process, including name, address, SSN, birthdate, and medical
record number. Admission date and date of discharge were retained. All
participants were given declassified case IDs when their cases were entered into the
Pneumonia Database, the source of this study’s data.
This study is IRB approved as Exempt because de-identified data was used and
further IRB approval was deemed not necessary by the IRB Office.

29

Study Cohort, Inclusion, and Exclusion Criteria
A total of 10,101 verified cases from HAPPI were available for use and were
eligible for study. Patients were excluded from analysis if they were lost to follow
up 1 year after their initial CAP hospitalization (n = 49). If a patient was unable to
reach by phone call, mortality was evaluated by reviewing medical records and
mortality data obtained from the Kentucky Department for Public Health Office of
Vital Statistics. SSNs were checked with the Kentucky Office of Vital Statistics to
see if any patient had died unreported.
Using the above criterion, 10,052 cases were included in this study cohort (n =
10,052).
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Description of Study Variables and Covariates
A. Definition of T2DM
2,734 T2DM patients were identified in the study cohort using the following
ADA criteria:30
(a) Past medical history listing T2DM and a HbA1c test value performed at
admission for CAP or done within six months prior to admission for CAP.
(b) Past medical history not listing T2DM prior to admission for CAP,
however, the patient was diagnosed with T2DM during their hospitalization, with
HBA1c values confirmatory for T2DM ( ≥ 6.5%).
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(c) Insulin-dependent diabetes was a variable collected in the HAPPI study.
541 patients were identified as T1DM and excluded from the T2DM cohort.

B. Definition of Statin Exposure
Statin use is defined by any class of statin on the patient’s home medication list
recorded on admission, confirmed by the HAPPI data collection team on review of
their electronic medical records (EMR) and outpatient medication list as recorded
by the hospital. The frequency of statins prescribed to the patient to be at least once
per day. Patients who discontinued statin therapy before CAP hospitalization were
excluded. Statin dosage was not among the variables recorded in the HAPPI study.

31

Using this criteria, 3605 patients with prior statin exposure were identified in
the study cohort.

C. Description of Covariates
Covariates for the regression model included all demographic variables,
medical co-morbidities, clinical conditions, and pharmaceutical usage associated
with CAP hospitalizations. Covariate data was acquired by the HAPPI study using
EMR and diagnostic coding (ICD-9 from 6/1/2014- 10/14/2015, ICD-10 after
10/15/2015).
The covariates considered and analyzed for the model include age ≥ 65 years,
race, sex, OW, OB, hospitalization in the past 90 days, direct admission to the ICU
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on CAP hospitalization, mechanical ventilation on admission, nursing home
residence, prior hospitalization within the past 90 days, history of renal disease,
active or recently diagnosed cancer, CAD, hypertension, congestive heart failure
(CHF), prior myocardial infarction (MI), and current medication usage of betablockers, warfarin or ACE-I.

Statistical Methods Analysis
The study design with the proposed statistical methods included decision tree
analysis, logistic regression and propensity score analysis (Figure 3.1). Using
propensity score matching (PSM) may reduce the bias due to confounding variables
that could be found in an estimate of the treatment effect obtained from simply
32

comparing outcomes among patients who were previously on statins versus those
that did not.

Sub-Analysis: Cost Analysis
Length of stay as an inpatient was a variable collected in the HAPPI study
through chart review, with dates of admission and discharge withheld. Total mean
costs for hospitalizations were estimated using mean length of stay in days between
patients with the T2DM/statin interaction and T2DM patients without prior statin
use.
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These values would then be used to calculate hospital cost estimates based on
the 2014-2016 aggregate data from the Agency for Healthcare Research and
Quality (AHRQ).

Statistical Tools
IBM SPSS Statistics 27 was used for all data processing and statistical analysis.
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Figure 3.1. Study Design and Statistical Methodology
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CHAPTER 4
RESULTS

Study Population Description
There were 10,052 CAP cases in the HAPPI study suitable for analysis after
excluding those patients lost to follow up after 1 year of their CAP hospitalization
and enrollment into the HAPPI study (n=49). Of these, 2734 cases were T2DM,
while the remaining 7318 had no T2DM diagnosis before or during their CAP
35

hospitalization.
Table 4.1 presents the demographic characteristics of the study population by
T2DM status. At baseline, there were significantly a higher proportion of nonCaucasians in the T2DM cohort (22.8%) than in the non-T2DM cohort (19.9%) (p
< 0.01). Hispanic ethnicity was not a category collected in the HAPPI dataset. By
gender, there was a higher percentage of females in the T2DM cohort (54.7%) than
in the non-T2DM cohort (53.4%), but this was not significant (p = 0.24). There is
a significantly lower percentage of T2DM patients under the age of 34 (2.2%) than
non-T2DM cases (5.5%) (p < 0.01). The majority of T2DM patients were in the 6080 age range. There was a significantly higher percentage of T2DM patients age 60
to 64 (12.1%) than non-T2DM patients (10.0%) (p < 0.01), and a significantly
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higher percentage of T2DM patients age 65-74 (24.8%) than non-T2DM cases
(21.3%) (p < 0.01). There was a significantly higher percentage of non-T2DM age
≥ 85 years (15.5%) than the T2DM (12.5%) (p < 0.01), implying that the T2DM
patients had a lower longevity than the non-T2DM patients.

Table 4.1. Baseline Patient Demographics
Characteristic

T2DM
(n = 2,734)

Non-T2DM
(n= 7,318)

P value

2108 (77.1)
572 (21.0)
51 (1.8)

5874 (80.3)
1361 (18.6)
83 (1.2)

<0.01
<0.01
0.02

Male

1238 (45.3)

3410 (46.6)

0.24

Female

1496 (54.7)

3908 (53.4)

0.24

15 (0.5)
46 (1.7)
155 (5.7)
309 (11.3)
283 (10.4)
330 (12.1)
677 (24.8)
576 (21.1)
343 (12.5)

115 (1.6%)
288 (3.9%)
455 (6.2%)
822 (11.2%)
709 (9.7%)
734 (10.0%)
1557 (21.3%)
1507 (20.6)
1131 (15.5)

<0.01
<0.01
0.35
0.89
0.30
<0.01
<0.01
0.58
<0.01

Race
Caucasian
African American
Other

Gender
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Age Groups
18 to 24
25 to 34 years
35 to 44 years
45 to 54 years
55 to 59 years
60 to 64 years
65 to 74 years
75 to 84 years
≥ 85 years

Data are represented as n (%).

A comparison of the percentage distribution of age groups between adults
hospitalized CAP and the overall adult Louisville population from 2016-2019 is
shown in Figure 4.1. Both T2DM and non-T2DM cohorts skew left in age
compared to the city at large, with the percentage of patients 65 and older
significantly higher in both cohorts than in the overall city population (p < 0.001).
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Comparisons of CAP patients’ demographics by race and gender to the adult
Louisville population from 2016-2019 are shown in Figure 4.2. Both T2DM and
non-T2DM cohort groups significantly have a higher percentage of Caucasians and
less non-black minorities in than the city population at large (p = 0.005). There is
no significant difference in gender between all three groups (p = 0.24).
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Figure 4.1 Comparison of percentage distribution of HAPPI patient age to the Louisville population: (blue) T2DM
patients hospitalized with CAP, (gray) non-T2DM patients hospitalized with CAP, (red) overall adult population of
Louisville from 2016-2019.
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Figure 4.2. Comparison of HAPPI patient race and gender demographics to the Louisville population: (blue) T2DM
patients hospitalized with CAP, (gray) non-T2DM patients hospitalized with CAP, (red) overall adult population of
Louisville from 2016-2019.
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Table 4.2 shows the prior medical history characteristics of the study
population. At baseline, the T2DM cohort had significantly higher prevalence of
cardiovascular disease, its sequalae, and cardiovascular treatment than the nonT2DM cohort. Patients in the T2DM cohort had higher prevalence of chronic
diseases such as hypertension (79.8% vs 32.6%), dyslipidemia (56.0% vs 40.0%),
coronary artery disease (37.5% vs 27.4%), chronic heart failure (36.2% vs 27.4%),
chronic renal disease (35.6% vs 26.1%), obesity (46.2% vs 30.7%), and prior
myocardial infarction (17.8% vs 11.7%) (Table 4.2). Patients in the T2DM cohort
were significantly more likely to report usage of cardiovascular drug treatments,
including statins (46.3% vs. 32.0%), beta blockers (47.2% vs 36.1%), and ACE
inhibitors (34.3% vs 25.5). Patients with T2DM had higher incidence of going
directly to the ICU (19.9% vs 16.1) and being mechanically ventilated (16.8% vs
40

12.3%) within the first 24 hours of their CAP hospitalization.
Patients in the non-T2DM cohort had a significantly higher prevalence for a
previous neoplastic disorder (15.0% vs 10.9%). There was no statistically
significant difference in the prevalence of COPD (49.4% vs 48.1%), OW (25.9%
vs 26.1%), smoking history (69.1% vs 69.6%), prior hospitalization in the past 90
days, or nursing home residence between the two groups.
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Table 4.2. Patient Medical History and Hospitalization Characteristics
Characteristic

T2DM
(n = 2,734)

Non-T2DM
(n= 7,318)

P value

Renal Disease
Cancer, any type
CAD
CHF
Hypertension
COPD
MI
DLP
OW
OB
Current or former smoker
Hospitalized in the previous 90 Days
Nursing home residence
Statin usage
Beta-Blocker usage

974 (35.6)
299 (10.9)
1026 (37.5)
991 (36.2)
2183 (79.8)
1351 (49.4)
487 (17.8)
1530 (56.0)
709 (25.9)
1262 (46.2)
1890 (69.1)
804 (29.4)
337 (12.3)
1265 (46.3)
1290 (47.2)

1909 (26.1)
2095 (15.0)
2008 (27.4)
2005 (27.4)
4817 (65.8)
3520 (48.1)
853 (11.7)
2926 (40.0)
1913 (26.1)
2247 (30.7)
5092 (69.6)
2109 (28.8)
929 (12.7)
2340 (32.0)
2639 (36.1)

<0.01
<0.01
<0.01
<0.01
<0.01
0.25
<0.01
<0.01
0.84
<0.01
0.63
0.56
0.59
<0.01
<0.01

ACE-I usage

939 (34.3)

1866 (25.5)

<0.01

544 (19.9)
468 (16.8)
107.7

1179 (16.1)
900 (12.3)
100.3

<0.01
<0.01
0.07

Past Medical History
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Hospitalization
Direct ICU admission
Ventilation on admission
Pneumonia Severity Index (mean)

Crosstabs
1265 HAPPI patients had the T2DM and statin interaction. 1469 HAPPI
patients had T2DM without a history of prior statin use. Of the 6447 HAPPI patients
who were non-T2DM, 2340 patients had prior statin exposure, while 4978 patients
were exposed to neither variable.
Contingency tables were employed to test if there was some association
between T2DM and statin use in CAP patients (Table 4.3) with the expected values
in paratheses. The chi-square statistic for the table was significant (x2 = 176.78, p
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< 0.0001), indicating that there is some association between T2DM and statin use
in CAP patients, with an odds ratio (OR) of 1.83 (95% confidence interval (CI):
1.68 – 2.00, p < 0.01). After the cross tabulations, decision tree analysis was
employed to see if statin exposure and T2DM are strongly related to morbidity and
mortality in CAP patients.

Table 4.3 Crosstabulation showing HAPPI patients by T2DM diagnosis and
previous statin usage with expected values for each group in parentheses.
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Decision Tree Analyses
A. Decision Tree Analysis of Mortality Outcomes at One Month
The classification tree produced by decision tree analysis found the most
important predictor of mortality at one month was T2DM status, followed by age ≥
65, and then statin use. (Figure 4.3) In the decision tree analysis, T2DM was a
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significant protective effect against mortality at one month (OR = 0.83: 95% CI
0.72-0.96, p = 0.01). Patients age ≥ 65 were at increased odds for death in both
diabetics (OR = 2.03: 95% CI 1.53-2.69) and non-diabetics (OR = 3.01: 95% CI
2.54-3.57), and these odds was significant for both populations (p < 0.0001 and p
< 0.0001, respectively).
Statin exposure had a significant protective effect against mortality at one month
in patients with T2DM and age < 65 (OR = 0.54: 95% CI 0.31-0.93, p = 0.03) and
in patients without T2DM and age ≥ 65 (OR = 0.75: 95% CI 0.63-0.89, p = 0.001).
Patients with T2DM and age ≥ 65 had a protective effect from statins against
mortality at one month (OR = 0.77: 95% CI 0.57-1.04, p = 0.09), however this was
not significant. Statin exposure was associated with an increased odds for mortality
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at one month in patients without T2DM and age < 65 (OR = 1.23: 95% CI 0.871.75), but this was not significant.

43

Figure 4.3. Decision tree analysis for mortality after one month based around history of T2DM, statin usage, and age.
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B. Decision Tree Analysis of Mortality Outcomes at Six Months
The decision tree analysis for death within six months of CAP hospitalization
(Figure 4.4) found T2DM had a protective effect against mortality (OR = 0.92: 95%
CI 0.82-1.02, p = 0.11), but this effect was not significant. The risk for death within
six months was significantly increased for patients age ≥ 65, in diabetics (OR = 2.1:
95% CI 1.72-2.58, p < 0.0001) and non-diabetics (OR = 2.7: 95% CI 1.72-2.58, p
< 0.0001).
Statin exposure was associated with a decreased odds against mortality at six
months in patients without T2DM and age ≥ 65 (OR = 0.82: 95% CI 0.71-0.94, p
= 0.005) that was significant, and a decreased odds in patients with T2DM and age
≥ 65 (OR = 0.8: 95% CI 0.64-1.00, p = 0.053) that approached significance. Patients
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with T2DM and age < 65 had a protective effect from statins against mortality at
six months (OR = 0.74: 95% CI 0.51-1.06, p = 0.10), however this was not
significant. Statin exposure was associated with an increased odds for mortality at
six months in patients without T2DM and age < 65 (OR = 1.27: 95% CI 0.99-1.9,
p = 0.058), that approached significance.
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Figure 4.4. Decision tree analysis for mortality after six months based around history of T2DM, statin usage, and age.
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C. Decision Tree Analysis of Mortality Outcomes at 12 Months
The decision tree analysis for all-cause mortality within 12 months of CAP
hospitalization (Figure 4.5) found T2DM trended toward a protective effect against
mortality (OR = 0.93: 95% CI 0.85-1.03, p = 0.22), but this effect was not
significant. As with mortality at one month and mortality at six months, age ≥ 65
was associated with a significant increased odds for death within 12 months in both
diabetics (OR = 2.12: 95% CI 1.77-2.55, p < 0.0001) and non-diabetics (OR = 2.62:
95% CI 2.35 -2.94, p < 0.0001).
Statin exposure was significantly associated with a decreased odds against
mortality at 12 months in patients with T2DM and age < 65 (OR = 0.69: 95% CI
0.50-0.96, p = 0.03) and patients without T2DM and age ≥ 65 (OR = 0.85: 95% CI
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0.74-0.96, p = 0.01). Statin exposure was associated with a protective effect against
mortality at 12 months in patients with T2DM and age ≥ 65 (OR = 0.88: 95% CI
0.71-1.08, p = 0.23), however this was not significant. Statin exposure was
associated with an increased odds for mortality at 12 months in patients without
T2DM and age < 65 (OR = 1.24: 95% CI 1.0-1.55, p = 0.051), that was significant.
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Figure 4.5. Decision tree analysis for all-cause mortality after 12 months based around history of T2DM, statin usage,
and age.
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D. Decision Tree Analysis of Morbidity Outcomes at One Month
The decision tree analysis for morbidity (Figure 4.6) found T2DM increased
the risk for CAP rehospitalization within one month of the initial admission (OR =
1.14: 95% CI 0.95-1.37, p = 0.17), but this effect was not significant. Statin
exposure had a protective effect against CAP rehospitalization within one month in
diabetics (OR = 0.88: 95% CI 0.65-1.2), whereas in non-diabetics, statin exposure
was associated with an increased odds for CAP rehospitalization (OR = 1.19: 95%
CI 0.96-1.46). Neither effect was significant (p = 0.43 and p = 0.11, respectively).
Age ≥ 65 was associated with a decreased odds of CAP rehospitalization in
patients with both the T2DM and statin interaction (OR = 0.69: 95% CI 0.49-1.11)
and in non-T2DM patients with statin exposure (OR = 0.94: 95% CI 0.65-1.35),
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however neither effect was significant (p = 0.12 and p = 0.72, respectively). Age ≥
65 was associated with a non-significant tendency toward an increased odds for
CAP rehospitalization in T2DM patients without statin exposure (OR = 1.19: 95%
CI 0.79-1.79, p = 0.42) and non-T2DM patients without statin exposure (OR = 1.08:
95% CI 0.84-1.38, p = 0.55).
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Figure 4.6. Decision tree analysis for morbidity (CAP rehospitalization) within one month based around history of
T2DM, statin usage, and age.
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E. Decision Tree Analysis of Morbidity Outcomes at Six Months
Decision tree analysis for CAP rehospitalization within six months (Figure 4.7)
found T2DM was associated with a significantly increased odds (OR = 1.22: 95%
CI 1.07-1.38, p = 0.003). Further down in the decision tree, the risk for CAP
rehospitalization was increased for both T2DM patients exposed to statins (OR =
1.04: 95% CI 0.84-1.29) and non-T2DM and statin exposed patients (OR = 1.14:
95% 0.98-1.32), but neither effect was significant (p = 0.73 and p = 0.09,
respectively).
Age ≥ 65 had a protective effect from CAP rehospitalization in patients with
the T2DM and statin interaction (OR = 0.86: 95% CI 0.62-1.18, p = 0.35), however
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not significantly. Interestingly, age ≥ 65 was associated with a non-significant
increased odds for CAP hospitalization in diabetic patients without prior statin
exposure (OR = 1.16: 95% CI 0.87-1.56, p = 0.32), in statin-exposed non-diabetic
patients (OR = 1.02: 95% CI 0.78-1.34, p = 0.87), and non-diabetic patients without
statin exposure (OR = 1.08: 95% CI 0.91-1.29, p = 0.37).
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Figure 4.7. Decision tree analysis for morbidity within six months based around history of T2DM, statin usage, and
age.
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F. Decision Tree Analysis of Mortality Outcomes at 12 Months
The decision tree analysis for morbidity (Figure 4.8) found T2DM patients had
a significantly increased odds for CAP rehospitalization within 12 months (OR =
1.22: 95% CI 1.09 -1.37, p = 0.001). Statin exposure was significantly associated
with an increased odds for CAP rehospitalization patients without T2DM (OR =
1.18: 95% CI 1.03-1.35, p = 0.01). Statin exposure was associated with a nonsignificant increased odds for CAP rehospitalization in T2DM patients (OR = 1.13:
95% CI 0.93 -1.38, p =0.21).
Age ≥ 65 had a non-significant trend toward a protective effect from CAP
rehospitalization in patients with the T2DM and statin interaction (OR = 0.78: 95%
CI 0.58-1.05, p = 0.10). Age ≥ 65 was associated with a non-significant risk for
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CAP hospitalization in T2DM patients without prior statin exposure (OR = 1.06:
95% CI 0.81-1.39, p = 0.67), in statin-exposed non-T2DM patients (OR = 1.02:
95% CI 0.79-1.29, p = 0.89), and in non-T2DM patients without statin exposure
(OR = 1.04: 95% CI 0.90-1.22, p = 0.56).
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Figure 4.8. Decision tree analysis for morbidity within 12 months based on T2DM, statin usage, and age.
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G. Summary of the Decision Tree Analysis Results
This present study found that statin use was significantly protective from
mortality at one month (p = 0.03) and at 12 months (p = 0.03) after CAP
hospitalization in T2DM cases under the age of 65 in the decision tree analysis.
Additionally, a protective effect from mortality at six months was also seen in
T2DM cases with statin exposure that was not significant (p = 0.10). For T2DM
cases age ≥ 65, the decision tree analysis found statin usage also was protective
from mortality at one month, six months, and 12 months, but none were significant
or only approached significance.
For non-T2DM cases, statin usage was significantly protective from mortality
at all three times for patients age ≥ 65. Interestingly, statin use was associated with
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increased mortality in non-T2DM patients at all three times but were not significant
or approached significance (p > 0.05).
The decision tree analysis for morbidity outcomes showed a trend for T2DM
cases age ≥ 65 on statins to have lower odds for CAP rehospitalization one month,
six months, and 12 months after their first hospitalization compared to T2DM cases
under 65 years old. However, these trends were not significant at all three time
frames (p > 0.05). Patients with T2DM and no prior statin usage age ≥ 65 showed
a trend for higher odds for CAP rehospitalization one month, six months, and 12
months after their first hospitalization compared to T2DM cases < 65 years old, but
these trends also were not significant (p > 0.05).
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In summary, the decision tree analysis showed that statin use was associated
with significantly lower odds ratios in T2DM patients age > 65 years for mortality
at one month (OR = 0.82: 95% CI 0.71-0.94, p = 0.005) and at 12 months (OR =
0.69: 95% CI 0.50-0.96, p = 0.03). In T2DM patients age ≥ 65, non-significantly
lower odds for mortality were observed. Statin use was associated with significantly
lower odds for mortality at one, six, and 12 months in non-T2DM patients age ≥ 65
but was associated with a higher odds for mortality in non-T2DM patients age <
65. The decision tree analysis found that statin use was associated with nonsignificant lower odds for CAP rehospitalization one, six, and 12 months after
admission for T2DM patients age ≥ 65. This association was not seen in the other
three groups (T2DM patients age < 65, non-T2DM patients age ≥ 65, and nonT2DM patients age < 65) for morbidity at one, six, and 12 months.
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Binary Logistic Regression Analysis: Mortality Outcomes
A. Logistic Regression for Mortality at One Month Overall
Binary logistic regressions analyses of mortality outcomes at one month, six
months and 12 months (dependent variables), using all independent study variables
for the regression model for mortality at one month were done (Table 4.4).
Originally, the model included the two study variables of interest (T2DM and prior
statin exposure), and an interaction variable (combined T2DM X statin use) that
indicated the effect of neither (non-T2DM with no statins), either (T2DM or
statins), or both T2DM and statins if the case had dual exposure, and all the
covariates as listed.
Through backwards stepwise elimination regression variable selection, the
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significant covariates that were significant for mortality in all at three time frames
(one month, six, months and 12 months) were identified: as race, gender, age ≥ 65,
OW, OB, history of neoplastic disease, history of a prior MI, direct admission to an
ICU, mechanical ventilation on day of admission, nursing home residence, and
being hospitalized within the past 90 days. These above covariates were used in the
final logistic regression model. Additional subgroup regression models were
stratified by age, gender, and race. (Supplementary Tables 4.1 – 4.8)
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Table 4.4. Regression Equation for Mortality at One Month
Variables in Equation

OR

SE

p

95% CI
Lower

Higher

Overall Mortality
T2DM
Statin
T2DM_Statin
Race: White
Sex: Male
Age ≥ 65
OW
Obese
Cancer
MI
Nursing home
Hospitalized in past 90 days
ICU on Admit
Intubation on Admit

0.95
0.85
0.87
1.43
1.17
2.23
0.65
0.57
3.03
1.26
2.97
1.38
2.54
1.80

0.10
0.09
0.16
0.36
0.07
0.08
0.09
0.09
0.08
0.10
0.07
0.07
0.09
0.10

0.60
0.07
0.39
<0.01
0.02
<0.01
<0.01
<0.01
<0.01
0.02
<0.01
<0.01
<0.01
<0.01

0.78
0.72
0.63
1.19
1.02
1.90
0.55
0.48
2.59
1.04
2.53
1.20
2.11
1.49

1.16
1.01
1.20
1.73
1.34
2.615
0.77
0.68
3.54
1.52
3.48
1.58
3.00
2.18

1.41
1.11
0.70
1.20
1.23
0.71
0.70
7.02
1.73
2.90
1.23
2.88
2.29

0.18
0.20
0.16
0.16
0.14
0.18
0.16
0.16
0.22
0.20
0.14
0.18
0.19

0.06
0.59
0.03
0.25
0.13
0.06
0.03
<0.01
0.01
<0.01
0.15
<0.01
<0.01

0.99
0.76
0.52
0.88
0.94
0.49
0.52
5.17
1.13
1.95
0.93
2.04
1.58

2.02
1.63
0.96
1.64
1.62
1.01
0.96
9.53
2.65
4.33
1.63
4.08
3.31

0.80
0.79
1.09
1.57
1.19
0.65
0.54
2.30
1.18
2.92
1.42
2.32
1.68

0.13
0.10
0.19
0.12
0.08
0.10
0.10
0.09
0.11
0.09
0.08
0.11
0.12

0.08
0.01
0.65
<0.01
0.03
<0.01
<0.01
<0.01
0.13
<0.01
<0.01
<0.01
<0.01

0.63
0.65
0.76
1.24
1.02
0.54
0.44
1.91
0.95
2.45
1.21
1.89
1.34

1.03
0.95
1.57
2.00
1.39
0.78
0.66
2.76
1.45
3.47
1.67
2.86
2.11

Mortality Age < 65 Years
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T2DM
Statin
T2DM x Statin
Race: White
Sex: Male
OW
Obese
Cancer
MI
Nursing home
Hospitalized in past 90 days
ICU on Admit
Intubation on Admit

Mortality Age ≥ 65 Years
T2DM
Statin
T2DM x Statin
Race: White
Sex: Male
OW
Obese
Cancer
MI
Nursing home
Hospitalized in past 90 days
ICU on Admit
Intubation on Admit
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Of 10,052 CAP patients, 1,113 patients had expired one month by after their
initial hospitalization (11.1%). The odds for mortality at one month was
significantly increased for patients age ≥ 65 years (OR = 2.23: 95% CI 1.9 – 2.62,
p <0.001), which was seen in the decision tree analysis for mortality at one month.
A history of statin use was protective against death at one month (OR = 0.85: 95%
CI 0.72-1.01), approaching significance (p = 0.06). T2DM (OR = 0.95: 95% CI
0.77-1.16, p = 0.6) and the T2DM-statin interaction (OR = 0.87: 95% CI 0.63-1.2,
p = 0.87) both tended toward protective effects against death at one month, but not
significantly. OW (OR = 0.65: 95% CI 0.55 – 0.77, p <0.0001) and OB patients
(OR = 0.57: 95% CI 0.48 – 0.68, p <0.0001) were at significantly decreased odds
for death at one month (p < 0.0001 and p < <0.0001, respectively). Notably, OB
was slightly more protective than OW, but not significantly.
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Increased odds for death after one month was also significantly associated with
Caucasian race (OR = 1.43: 95% CI 1.19– 1.73, p <0.0001), male gender (OR =
1.17: 95% CI 1.02 – 1.34, p = 0.02), a history of neoplastic disease (OR = 3.02:
95% CI 2.59 – 3.54, p <0.0001), a prior MI (OR = 1.26: 95% CI 1.04-1.52, p =
0.02), direct admission to an ICU (OR = 2.5: 95% CI 2.11 – 3.00, p <0.0001),
mechanical ventilation on admission (OR = 1.8: 95% CI 1.49– 2.18, p <0.0001),
nursing home residence (OR = 2.97: 95% CI 2.53– 3.48, p <0.0001) and being
hospitalized in the past 90 days (OR = 1.38: 95% CI 1.2 – 1.58, p <0.0001).
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B. Logistic Regression for Mortality at One Month Age < 65 Years
Regression analysis of mortality at one month were done comparing separately
age < 65 vs age ≥ 65 years (Table 4.4). 256 out of 4261 patients < 65 years old
expired by at one month after CAP hospitalization (6.0%). In this population, the
T2DM and statin interaction was significantly associated with a decreased odds of
death at after one month (OR = 0.45: 95%CI 0.23-0.9, p = 0.02). This protective
association for cases < 65 years was seen in the corresponding decision tree, as
previously discussed above.
T2DM increased the odds for death in patients age < 65 (OR = 1.41: 95% CI
0.99-2.02) that approached significance (p = 0.056). Statin exposure (OR = 1.11:
95% CI 0.76-1.63, p = 0.59), male gender (OR = 1.23: 95% CI 0.94 – 1.62, p =
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0.13), Caucasian race (OR = 1.2: 95% CI 0.88– 1.64, p = 0.25) and being
hospitalized in the past 90 days (OR = 1.23: 95% CI 0.92 – 1.63, p = 0.15) were
statistically non-significant, but also tended towards an increased odds for death.
Obesity had a significantly protective effect against mortality at one month (OR
= 0.7: 95% CI 0.52 – 0.96, p =0.03) while overweight cases had a protective effect,
also approaching significance (OR = 0.71: 95% CI 0.49 – 1.01, p = 0.058). An
increased odds for death at one month was significantly associated with a history
of neoplastic disease (OR = 7.02: 95% CI 0.5.17 – 9.53, p <0.0001), a prior MI
(OR = 1.73: 95% CI 1.13-12.65, p = 0.01), direct admission to an ICU (OR = 2.88:
95% CI 2.03 – 4.08 p <0.0001), mechanical ventilation on admission (OR = 2.29:
95% CI 1.58– 3.31, p <0.0001), and nursing home residence (OR = 2.90: 95% CI
1.95– 4.33, p <0.0001).
60

C. Logistic Regression for Mortality at One Month Age ≥ 65 Years
Among patients ≥ 65 years old (Table 4.4), 857 of 5791 expired at one
month after CAP hospitalization (14.8%). The T2DM and statin interaction
was associated with a non-significant increased odds of death at one month
(OR = 1.09: 95% CI 0.76-1.57, p = 0.65). Statin exposure alone was
significantly associated with a decreased odds of death after one month (OR =
0.79: 95%CI 0.65-0.95, p = 0.01). T2DM was protective against mortality at
one month in this subgroup (OR = 0.80: 95% CI 0.63-1.03) approaching
significance (p = 0.078). OW (OR = 0.65: 95% CI 0.54-0.78, p <0.0001) and
OB (OR = 0.54: 95% CI 0.44-0.66 p <0.0001) had a significantly protective
effect against death at one month.
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Risk for death at one month was significantly associated with Caucasian
race (OR = 1.57: 95% CI 1.24– 2.00, p <0.0001), male gender (OR = 1.19:
95% CI 1.02 – 1.39, p = 0.03), a history of neoplastic disease (OR = 2.30: 95%
CI 1.91 – 2.76, p <0.0001), direct admission to an ICU (OR = 2.32: 95% CI
1.89 – 2.86, p <0.0001), mechanical ventilation on admission (OR = 1.68: 95%
CI 1.34– 2.11, p <0.0001), nursing home residence (OR = 2.92: 95% CI 2.45–
3.47, p <0.0001) and being hospitalized in the past 90 days (OR = 1.42: 95%
CI 1.2 – 1.67, p <0.0001). History of a prior MI (OR = 1.18: 95% CI 0.95-1.45,
p = 0.13) was not significant.
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D. Logistic Regression for Mortality of Mortality at Six Months Overall
Of 10,052 HAPPI Study CAP patients, 2141 patients (21.1%) expired by six
months after their CAP hospitalization. (Table 4.5). The mortality rate is
cumulative, including 1113 patients who died by one month after hospitalization.
T2DM was associated with a non-significant increased likelihood of death at
six months, (OR = 1.08: 95% 0.92 - 1.26, p = 0.35). But T2DM was associated with
a non-significant decreased odds for death in the decision tree analysis, pointing to
a non-significant effect. Odds for death at six months was significantly increased
for patients age ≥ 65 years (OR = 2.08: 95% CI 1.84 – 2.34, p <0.0001), as shown
in decision tree analysis.
Statin exposure alone (OR = 0.95: 95% CI 0.83-1.08, p = 0.4) and the
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T2DM/statin interaction (OR = 0.86: 95% CI 0.67-1.09, p = 0.20) had a nonsignificant decrease likelihood for mortality at six months.
OW (OR = 0.65: 95% CI 0.57 – 0.74, p <0.0001) and OB (OR = 0.51: 95% CI
0.45 – 0.58, p <0.0001) patients had a significantly decreased odds for death at six
months. An increased odds for death at six months was significantly associated with
Caucasian race (OR = 1.31: 95% CI 1.14– 1.51, p <0.0001), male gender (OR =
1.16: 95% CI 1.05 – 1.29, p = 0.01), a history of neoplastic disease (OR = 3.49:
95% CI 3.07– 3.98, p <0.0001), a prior MI (OR = 1.35: 95% CI 1.17-1.57, p
<0.0001), direct admission to an ICU (OR = 1.8: 95% CI 1.51 – 2.09, p <0.0001),
mechanical ventilation on admission (OR = 1.78: 95% CI 1.51– 2.09, p <0.0001),
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nursing home residence (OR

= 2.77: 95% CI 2.42– 3.18, p <0.0001) and

hospitalization in the past 90 days (OR = 1.70: 95% CI 1.52 – 1.90, p <0.0001).
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Table 4.5. Regression Equation for Mortality at Six Months
Variables in Equation

OR

SE

p

95% CI
Lower

Higher

Overall Mortality
T2DM
Statin
T2DM x Statin
Race: White
Sex: Male
Age ≥ 65
OW
Obese
Cancer
MI
Nursing home
Hospitalized in past 90 days
ICU on Admit
Intubation on Admit

1.08
0.95
0.86
1.37
1.16
2.08
0.65
0.51
3.49
1.35
2.77
1.70
1.80
1.78

0.08
0.07
0.12
0.07
0.05
0.06
0.07
0.07
0.07
0.08
0.07
0.06
0.08
0.08

0.35
0.40
0.20
<0.01
0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01

0.92
0.83
0.67
1.14
1.05
1.84
0.57
0.45
3.07
1.17
2.42
1.52
1.55
1.51

1.26
1.08
1.09
1.51
1.29
2.34
0.74
0.58
3.98
1.57
3.18
1.90
2.09
2.09

1.39
1.15
0.59
1.46
1.23
0.70
0.64
7.98
1.82
2.33
1.89
1.70
2.11

0.14
0.14
0.24
0.12
0.10
0.13
0.12
0.12
0.16
0.17
0.10
0.14
0.15

0.01
0.34
0.03
0.001
0.04
0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01

1.07
0.87
0.37
1.16
1.01
0.54
0.51
6.30
1.34
1.69
1.55
1.30
1.58

1.82
1.51
0.95
1.84
1.50
0.90
0.81
10.10
2.46
3.22
2.31
2.23
2.83

0.96
0.88
0.99
1.23
1.18
0.63
0.46
2.49
1.26
2.79
1.62
1.79
1.71

0.10
0.08
0.15
0.09
0.06
0.08
0.08
0.08
0.09
0.08
0.07
0.09
0.10

0.69
0.11
0.93
0.03
0.01
<0.01
<0.01
<0.01
0.01
<0.01
<0.01
<0.01
<0.01

0.79
0.76
0.74
1.02
1.04
0.55
0.39
2.13
1.06
2.40
1.42
1.49
1.40

1.17
1.03
1.31
1.47
1.34
0.73
0.54
2.91
1.48
3.24
1.84
2.15
2.08

Mortality Age < 65 Years
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T2DM
Statin
T2DM x Statin
Race: White
Sex: Male
OW
Obese
Cancer
MI
Nursing home
Hospitalized in past 90 days
ICU on Admit
Intubation on Admit

Mortality Age ≥ 65 Years
T2DM
Statin
T2DM x Statin
Race: White
Sex: Male
OW
Obese
Cancer
MI
Nursing home
Hospitalized in past 90 days
ICU on Admit
Intubation on Admit
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E. Logistic Regression for Mortality at Six Months Age < 65 Years
Regression analyses of mortality at six months were done comparing separately
< age 65 vs age ≥ 65 years (Table 4.5). 551 of 4261 patients were < 65 years and
expired at six months after CAP hospitalization (12.9%). The T2DM and statin
interaction (OR = 0.59: 95% CI 0.37-0.95, p = 0.03) was associated with a
significant decreased odds of death after six months. Notably, the T2DM and statin
interaction was not significant in the decision tree analysis. Risk for death at six
months was significantly associated with T2DM (OR = 1.39: 95% CI 1.07 – 1.81 p
= 0.01) as found in the decision tree analysis.
OW (OR = 0.65: 95% CI 0.54-0.78, p <0.0001) and obese (OR = 0.54: 95% CI
0.44-0.66 p <0.0001) patients had a significantly protective effect against death at
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six months. Interestingly, statin exposure was associated a non-significant risk of
death at six months in patients < 65 (OR = 1.15: 95% CI 0.87 – 1.51, p = 0.34).
A significantly increased odds for death at six months was associated with
T2DM alone (OR = 1.39: 95% CI 1.07 – 1.81 p = 0.01), Caucasian race (OR =
1.46: 95% CI 1.16 – 1.84, p = 0.001), male gender (OR = 1.23: 95% CI 1.01 – 1.5,
p = 0.037), a history of neoplastic disease (OR = 7.98: 95% CI 6.30 – 10.09, p
<0.0001), direct admission to an ICU (OR = 1.7: 95% CI 1.30– 2.23, p <0.0001),
mechanical ventilation on admission (OR = 2.11: 95% CI 1.58– 2.83, p <0.0001),
nursing home residence (OR = 2.33: 95% CI 1.69– 3.22, p <0.0001), prior MI (OR
= 1.82: 95% CI 1.34– 2.46, p <0.0001), and hospitalization in the past 90 days (OR
= 1.89: 95% CI 1.55 – 2.31, p <0.0001).
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F. Logistic Regression for Mortality at Six Months Age ≥ 65 Years
1590 of 5791 patients age ≥ 65 (27.5%) expired at 6 months after CAP
hospitalization (Table 4.5). T2DM alone (OR = 0.96: 95% CI 0.79-1.17, p = 0.69),
statin exposure alone (OR = 0.88: 95% CI 0.76-1.03, p = 0.11), and the T2DM and
statin interaction (OR = 0.99: 95% CI 0.74-1.31, p = 0.93) were not significantly
associated with a decreased odds for mortality. The decision tree analysis also
found a statistically non-significant lower odds for death in patients ≥ 65 years for
the T2DM and statin interaction.
OW (OR = 0.65: 95% CI 0.54-0.78, p <0.001) or OB (OR = 0.54: 95% CI 0.440.66 p <0.001) patients age ≥ 65 had a significant protective effect against death at
six months.
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Odds for death at six months was significantly associated with Caucasian race
(OR = 1.23: 95% CI 1.02 – 1.47, p = 0.03), male gender (OR = 1.18: 95% CI 1.04
– 1.34, p = 0.01), a history of neoplastic disease (OR = 2.49: 95% CI 2.13 – 2.91,
p <0.0001), direct admission to an ICU (OR = 1.79: 95% CI 1.49– 2.15, p <0.0001),
mechanical ventilation on admission (OR = 1.71: 95% CI 1.41– 2.08, p <0.0001),
nursing home residence (OR = 2.79: 95% CI 2.40– 3.24, p <0.0001), prior MI (OR
= 1.26: 95% CI 1.06–1.48, p <0.0001), and hospitalization in the past 90 days (OR
= 1.62: 95% CI 1.42 – 1.84, p <0.0001).
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G. Logistic Regression for Mortality of Mortality at 12 Months Overall
2756 of 10052 patients (27.4%) expired within 12 months after CAP
hospitalization (Table 4.6). This number is cumulative, including all deaths at one
month and six months after hospitalization. An increased odds for death at 12
months was significantly associated with age ≥ 65 years (OR = 2.05: 95% CI 1.84
– 2.28, p <0.001), while T2DM was associated with a non-significant increased
odds of death after 12 months (OR = 1.10: 95% 0.95 - 1.27, p = 0.22), similar to
the decision tree analysis. Statin exposure alone (OR = 0.96: 95% CI 0.85-1.09, p
= 0.53), and the T2DM and statin interaction (OR = 0.87: 95% CI 0.70-1.09, p =
0.23) were associated with a non-significant decreased odds for mortality.
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Table 4.6. Regression Equation for All-Cause Mortality at 12 Months
Variables in Equation

OR

SE

p

95% CI
Lower

Higher

Overall Mortality
T2DM
Statin
T2DM x Statin
Race: White
Sex: Male
Age ≥ 65
OW
Obese
Cancer
MI
Nursing home
Hospitalized in past 90 days
ICU on Admit
Intubation on Admit

1.10
0.96
0.87
1.30
1.18
2.05
0.64
0.53
3.57
1.41
2.62
1.81
1.70
1.71

0.07
0.06
0.11
0.07
0.05
0.06
0.06
0.06
0.06
0.07
0.07
0.05
0.07
0.08

0.22
0.53
0.23
<0.001
0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

0.95
0.85
0.70
1.14
1.07
1.84
0.56
0.47
3.15
1.23
2.30
1.64
1.48
1.46

1.27
1.09
1.09
1.48
1.30
2.28
0.72
0.59
4.04
1.62
2.99
2.01
1.96
1.99

1.42
1.09
0.55
1.40
1.16
0.61
0.62
8.49
2.03
2.38
2.08
1.62
1.91

0.12
0.13
0.22
0.10
0.09
0.12
0.10
0.12
0.14
0.15
0.09
0.13
0.14

0.004
0.50
0.006
0.001
0.10
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

1.12
0.85
0.36
1.14
0.97
0.49
0.50
6.78
1.54
1.77
1.74
1.26
1.46

1.80
1.40
0.85
1.72
1.39
0.78
0.76
10.64
2.67
3.21
2.49
2.08
2.51

0.96
0.90
1.06
1.24
1.23
0.64
0.48
2.41
1.27
2.60
1.68
1.68
1.69

0.09
0.07
0.14
0.09
0.06
0.07
0.08
0.08
0.08
0.08
0.06
0.09
0.10

0.63
0.16
0.67
0.01
0.001
<0.001
<0.001
<0.001
0.003
<0.001
<0.001
<0.001
<0.001

0.79
0.79
0.81
1.05
1.09
0.55
0.42
2.08
1.08
2.25
1.49
1.42
1.39

1.15
1.04
1.38
1.47
1.38
0.73
0.56
2.81
1.49
3.02
1.91
2.02
2.04

Mortality Age < 65 Years
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T2DM
Statin
T2DM x Statin
Race: White
Sex: Male
OW
Obese
Cancer
MI
Nursing home
Hospitalized in past 90 days
ICU on Admit
Intubation on Admit

Mortality Age ≥ 65 Years
T2DM
Statin
T2DM x Statin
Race: White
Sex: Male
OW
Obese
Cancer
MI
Nursing home
Hospitalized in past 90 days
ICU on Admit
Intubation on Admit
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OW (OR = 0.64: 95% CI 0.56 – 0.72, p <0.0001) or OB (OR = 0.53: 95% CI
0.47– 0.59, p <0.0001) patients had a significantly decreased odds for death at 12
months. An increased odds for death at 12 months was significantly associated with
Caucasian race (OR = 1.299: 95% CI 1.14– 1.48, p <0.0001), male gender (OR =
1.18: 95% CI 1.07– 1.30, p = 0.01), a history of neoplastic disease (OR = 3.57:
95% CI 3.15-4.04, p <0.0001), a prior MI (OR = 1.41: 95% CI 1.23-1.62, p
<0.0001), direct admission to an ICU (OR = 1.70: 95% CI 1.48 – 1.96, p <0.0001),
mechanical ventilation on admission (OR = 1.71: 95% CI 1.46– 1.99, p <0.0001),
nursing home residence (OR

= 2.62: 95% CI 2.30– 2.99, p <0.0001) and

hospitalization in the past 90 days (OR = 1.81: 95% CI 1.64 – 2.01, p <0.0001).
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H. Logistic Regression for Mortality at 12 Months Age < 65 Years
Regression analysis of mortality at 12 months were done comparing separately
age < 65 vs age ≥ 65 years (Table 4.6). 750 of 4261 patients age < 65 (17.6%)
expired at 12 months after CAP hospitalization. As with the age <65 population at
one month and six months, the T2DM and statin interaction (OR = 0.55: 95% CI
0.36-0.85, p = 0.01) was significantly associated with a decreased odds of death
after 12 months. This significant relationship was also identified in the decision tree
analysis. Statin exposure alone was associated with an increased odds of death
within 12 months, but this was not significant (OR = 1.09: 95% CI 0.85 – 1.41, p =
0.50), while a significant increased odds for death within 12 months was associated
with T2DM alone (OR = 1.42 95% CI 1.12 – 1.80, p = 0.004).
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OW (OR = 0.61: 95% CI 0.49-0.78, p <0.0001) or obese (OR = 0.62: 95% CI
0.50-0.76 p <0.0001) patients had a significant protective effect against death
within 12 months. A significantly increased mortality risk at 12 months was
associated with Caucasian race (OR = 1.40: 95% CI 1.14– 1.72, p = 0.001), a
history of neoplastic disease (OR = 8.49: 95% CI 6.78 – 10.64, p <0.0001), direct
admission to an ICU (OR = 1.62: 95% CI 1.26– 2.08, p <0.0001), mechanical
ventilation on admission (OR = 1.91: 95% CI 1.46– 2.51, p <0.0001), nursing home
residence (OR = 2.38: 95% CI 1.77– 3.21, p <0.0001), prior MI (OR = 2.03: 95%
CI 1.54– 2.67, p <0.0001), and hospitalization in the past 90 days (OR = 2.08:
95% CI 1.74 – 2.49, p <0.0001). Male gender was associated with a non-significant
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increased odds for death within 12 months (OR = 1.16: 95% CI 0.97 - 1.39, p =
0.095).

I. Logistic Regression for Mortality at 12 Months Age ≥ 65 Years
2006 of 5791 patients ≥ 65 years (34.6%) had expired at 12 months after CAP
hospitalization (Table 4.6). The T2DM and statin interaction (OR = 0.99: 95% CI
0.74-1.31, p = 0.93) suggested a non-significant increased odds of mortality at 12
months (OR = 1.06: 95% CI 0.81-1.39, p = 0.67), which agrees with the decision
tree analysis. T2DM (OR = 0.96: 95% CI 0.79-1.15, p = 0.63) and statin exposure
(OR = 0.904: 95% CI 0.79-1.04, p = 0.16), were not significantly associated with a
decreased odds for mortality.
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OW (OR = 0.64: 95% CI 0.55-0.73, p <0.0001) or obese (OR = 0.48: 95% CI
0.42-0.60 p <0.0001) patients were significantly protected against death within 12
months. An increased odds for death within 12 months was significantly associated
Caucasian race (OR = 1.24: 95% CI 1.05 – 1.47, p = 0.01), male gender (OR =
1.23: 95% CI 1.09 – 1.38, p = 0.001), a history of neoplastic disease (OR = 2.41:
95% CI 2.08 – 2.81, p <0.0001), direct admission to an ICU (OR = 1.69: 95% CI
1.42– 2.02, p <0.0001), mechanical ventilation on admission (OR = 1.68: 95% CI
1.39– 2.04, p <0.0001), nursing home residence (OR = 2.60: 95% CI 2.25 – 3.02,
p <0.0001), prior MI (OR = 1.27: 95% CI 1.08–1.49, p = 0.003) and hospitalization
in the past 90 days (OR = 1.68: 95% CI 1.49 – 1.91, p <0.0001).
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J. Summary of the Regression Analysis for Mortality Outcomes
Binary regression analyses conducted showed that the T2DM and statin
interaction had a significant protective effect against mortality in CAP when
stratified for age and concurs with the decision tree analyses that the interaction is
protective against mortality in the age < 65 subgroup but not in the age ≥ 65
subgroup. T2DM was significantly associated with increased odds for mortality at
six months and 12 months for cases age > 65, but not the older age group. OW and
OB were significantly protective against mortality at one, six, and 12 months,
regardless of age.
Prior history of cardiovascular disease (i.e. prior MI), neoplastic disease, or
conditions that indicated frailty (i.e. nursing home residence), or increased CAP
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severity (i.e. direct ICU admission or direct mechanical ventilation on admission)
were significantly associated with increased odds for mortality at one, six, and 12
months, regardless of age. Male sex and Caucasian race also were significantly
associated with increased odds for mortality at one, six, and 12 months, regardless
of age.
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Binary Logistic Regression Analysis: Morbidity Outcomes
A. Logistic Regression for Morbidity at One Month Overall
Binary logistic regression analyses of morbidity outcomes at one, six, and 12
months with all covariates used in the mortality regression models, except the
variable “hospitalized within the past 90 days,” because of redundancy with
readmittance for CAP hospitalization. 583 of 10052 patients (5.8 %) were
readmitted for CAP one month after their initial hospitalization (Table 4.7.)
The T2DM/statin interaction was not significantly but tended towards a
protective effect against rehospitalization for CAP within one month (OR = 0.74:
95% CI 0.51-1.07). The decision tree analysis indicated a similar non-significant
protective effect with the T2DM/statin interaction.
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OW (OR = 0.95: 95% CI 0.77-1.17, p = 0.65) and age ≥ 65 (OR = 0.94: 95%
CI 0.78– 1.13, p = 0.50) were not significantly protective, but direct admission to
an ICU (OR = 0.79: 95% CI 0.60 – 1.04, p = 0.09) tended toward a protective effect
against CAP rehospitalization within one month. OB patients (OR = 0.80: 95% CI
0.65 – 0.98, p = 0.03) had a significantly decreased odds for CAP rehospitalization
within one month. Odds of CAP rehospitalization within one month was random
with respect to male gender (OR = 0.98: 95% CI 0.85 – 1.19, p = 1.00). CAP
rehospitalization risk within one month was significantly increased for patients with
T2DM (OR = 1.31: 95% CI 1.03 – 1.67, p = 0.03), a history of neoplastic disease
(OR = 1.29: 95% CI 1.031 – 1.62, p = 0.03), mechanical ventilation on admission
(OR = 1.35: 95% CI 1.02– 1.80, p = 0.036), and a prior MI (OR = 1.31: 95% CI
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1.04-1.66, p = 0.02). Statin exposure alone (OR = 1.17: 95% CI 0.94 – 1.45, p =
0.17) had a non-significantly increased odds for CAP rehospitalization.
Table 4.7 Regression Equation for CAP Rehospitalization by One Month
Variables in Equation

OR

SE

p

95% CI
Lower

Higher

Overall Morbidity
T2DM
Statin
T2DM x Statin
Race: White
Sex: Male
Age ≥ 65
OW
Obese
Cancer
MI
Nursing home
ICU on Admit
Intubation on Admit
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1.31
1.17
0.74
0.98
0.99
0.94
0.95
0.80
1.29
1.31
1.04
0.79
1.35

0.12
0.11
0.19
0.11
0.09
0.09
0.11
0.11
0.12
0.12
0.13
0.14
0.15

0.03
0.17
0.11
0.85
0.97
0.50
0.65
0.03
0.03
0.02
0.76
0.09
0.04

1.03
0.94
0.51
0.79
0.84
0.78
0.77
0.65
1.03
1.04
0.81
0.60
1.02

1.67
1.45
1.07
1.21
1.18
1.13
1.17
0.98
1.62
1.66
1.34
1.04
1.80

1.28
1.31
0.96
1.13
0.95
0.75
0.59
1.07
1.22
1.24
0.70
1.79

0.18
0.19
0.31
0.15
0.13
0.17
0.16
0.21
0.21
0.25
0.22
0.22

0.18
0.16
0.88
0.41
0.70
0.09
0.001
0.74
0.34
0.40
0.10
0.01

0.89
0.90
0.53
0.84
0.73
0.53
0.43
0.71
0.80
0.76
0.46
1.17

1.83
1.90
1.74
1.52
1.23
1.05
0.80
1.23
1.85
2.02
1.07
2.73

1.34
1.09
0.62
0.84
1.03
1.12
0.99
1.43
1.35
0.98
0.82
1.07

0.17
0.14
0.25
0.15
0.11
0.14
0.14
0.14
0.14
0.15
0.19
0.20

0.08
0.55
0.05
0.25
0.83
0.42
0.98
0.02
0.04
0.87
0.30
0.74

0.96
0.83
0.38
0.62
0.82
0.56
0.76
1.07
1.02
0.73
0.57
0.73

1.87
1.42
1.00
1.13
1.28
1.45
1.31
1.85
1.79
1.32
1.19
1.57

Morbidity Age < 65 Years
T2DM
Statin
T2DM x Statin
Race: White
Sex: Male
OW
Obese
Cancer
MI
Nursing home
ICU on Admit
Intubation on Admit

Morbidity Age ≥ 65 Years
T2DM
Statin
T2DM x Statin
Race: White
Sex: Male
OW
Obese
Cancer
MI
Nursing home
ICU on Admit
Intubation on Admit
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B. Logistic Regression for Morbidity at One Month Age < 65 Years
Morbidity within one month < age 65 years and those age ≥ 65 years was
analyzed in separate logistic regressions (Table 4.7). 244 of the 4261 patients age
< 65 years (5.7%) were readmitted for CAP by one month after initial CAP
hospitalization. In this population, the T2DM/statin interaction (OR = 0.95: 95%CI
0.53-1.74, p = 0.88), being overweight (OR = 0.75: 95%CI 0.53 – 1.05, p = 0.09),
male gender (OR = 0.95: 95% CI 0.73 – 1.23, p = 0.70), and direct admission to an
ICU (OR = 0.70: 95% CI 0.46 – 1.07, p = 0.10) were not significantly associated
with a decreased odds of CAP rehospitalization after one month.
T2DM (OR = 1.28: 95% CI 0.89-1.83, p = 0.18), statin exposure (OR = 1.31:
95% CI 0.90-1.90, p = 0.16), Caucasian race (OR = 1.13: 95% CI 0.84-1.52, p =
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0.41), nursing home residence (OR = 1.24: 95% CI 0.76 – 2.02, p = 0.40) and prior
MI (OR = 1.22: 95% CI 0.80 – 1.85, p = 0.36) were not associated with a significant
increased odds of rehospitalization. OB was significantly protective against CAP
rehospitalization within one month (OR = 0.59: 95% CI 0.43 – 0.80, p =0.001).
ODDS for CAP readmission by one month was significantly associated with
mechanical ventilation on admission (OR = 1.79: 95% CI 1.17 – 2.73, p = 0.007)
(Table 4.7).

C. Logistic Regression for Morbidity at One Month Age ≥ 65 Years
Among 5791 patients ≥ 65 years old, 339 (5.9%) were readmitted for CAP by
one month after their initial hospitalization. The T2DM/statin interaction had a
protective effect against CAP rehospitalization by one month (OR = 0.62: 95% CI
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0.38-1.01, p = 0.05). OB (OR = 1.00: 95% CI 0.76-1.31, p = 0.98), Caucasian race
(OR = 0.84: 95% CI 0.62 – 1.13, p = 0.25), direct admission to an ICU (OR = 0.82:
95% CI 0.57 – 1.19, p = 0.30) and nursing home residence (OR = 0.98: 95% CI
0.73 – 1.32, p = 0.87) were not significantly associated with CAP rehospitalization
by one month (Table 4.7).
Increased odds for rehospitalization by one month was significantly associated
with a history of neoplastic disease (OR = 1.40: 95% CI 1.07 – 1.85, p = 0.02) and
prior MI (OR = 1.35: 95% CI 1.02-1.79, p = 0.04). T2DM (OR = 1.34: 95% CI
0.96-1.87) associated with CAP rehospitalization within one month that
approached significance (p = 0.08). Statin exposure (OR = 1.09: 95% CI 0.831.421, p = 0.55), being overweight (OR = 1.12: 95% CI 0.86 – 1.45, p = 0.42), male
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gender (OR = 1.03: 95% CI 0.82 – 1.28, p = 0.83), and mechanical ventilation on
admission (OR = 1.07: 95% CI 0.73– 1.57, p = 0.74) were not significantly
associated with a risk for CAP rehospitalization by one month (Table 4.7).
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D. Logistic Regression for Morbidity at Six Months Overall
1281 patients (12.7%) were readmitted for CAP within six months after their
initial hospitalization (Table 4.8). OW (OR = 0.91: 95% CI 0.79 – 1.06, p = 0.23),
the T2DM/statin interaction (OR = 0.91: 95% CI 0.70-1.18, p = 0.48), Caucasian
race (OR = 0.95: 95% CI 0.82– 1.10, p = 0.50), and male gender (OR = 0.95: 95%
CI 0.84 – 1.07, p = 0.40) were associated with a non-significant decreased odds for
CAP rehospitalization by six months. OB had a protective effect against CAP
rehospitalization by six months that approached significance (OR = 0.88: 95% CI
0.76 – 1.02, p = 0.08).
CAP rehospitalization by six months was significantly associated with T2DM
(OR = 1.26: 95% CI 1.06 – 1.50, p = 0.008), a prior MI (OR = 1.26: 95% CI 1.0677

1.48, p = 0.008), mechanical ventilation on admission (OR = 1.25: 95% CI 1.02 –
1.53, p = 0.03), a history of neoplastic disease (OR = 1.12: 95% CI 1.03 – 1.43, p
= 0.02) and direct admission to an ICU (OR = 0.82: 95% CI 0.68 – 0.999, p =
0.05). Statin exposure alone (OR = 1.10: 95% CI 0.95-1.30, p = 0.18), age ≥ 65
years (OR = 1.01: 95% CI 0.89 – 1.14, p = 0.92), and nursing home residence (OR
= 1.05: 95% CI 0.88 – 1.25, p = 0.63) were not significantly associated with CAP
rehospitalization by six months (Table 4.8).
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Table 4.8. Regression Equation for CAP Rehospitalization by Six Months

Variables in Equation

B

SE

p

95% CI
Lower

Higher

Overall Morbidity
T2DM
Statin
T2DM x Statin
Race: White
Sex: Male
Age ≥ 65
OW
Obese
Cancer
MI
Nursing home
ICU on Admit
Intubation on Admit

1.26
1.11
0.91
0.95
0.95
1.01
0.91
0.88
1.21
1.26
1.05
0.82
1.25

0.09
0.08
0.13
0.08
0.06
0.07
0.08
0.07
0.08
0.09
0.09
0.10
0.10

0.01
0.18
0.48
0.50
0.40
0.92
0.23
0.08
0.02
0.01
0.63
0.05
0.03

1.06
0.95
0.70
0.82
0.84
0.89
0.79
0.76
1.03
1.06
0.88
0.68
1.02

1.50
1.30
1.18
1.10
1.07
1.14
1.06
1.02
1.43
1.48
1.25
0.99
1.53

1.24
1.14
1.07
0.93
0.90
0.74
0.75
1.31
1.32
1.31
0.75
1.49

0.09
0.14
0.22
0.10
0.10
0.13
0.11
0.14
0.15
0.18
0.16
0.16

0.63
0.34
0.77
0.48
0.24
0.02
0.01
0.06
0.07
0.14
0.06
0.01

0.79
0.87
0.70
0.76
0.74
0.57
0.60
0.99
0.98
0.92
0.55
1.09

1.15
1.49
1.64
1.14
1.08
0.95
0.93
1.74
1.77
1.86
1.01
2.03

1.29
1.07
0.83
0.97
0.99
1.03
0.99
1.16
1.23
0.98
0.86
1.10

0.12
0.10
0.17
0.11
0.08
0.09
0.10
0.10
0.10
0.11
0.13
0.14

0.04
0.47
0.27
0.80
0.92
0.73
0.92
0.15
0.05
0.82
0.24
0.50

1.02
0.89
0.59
0.78
0.85
0.86
0.82
0.95
1.00
0.79
0.67
0.84

1.63
1.30
1.16
1.21
1.16
1.25
1.20
1.42
1.50
1.20
1.11
1.43

Morbidity Age < 65 Years
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T2DM
Statin
T2DM x Statin
Race: White
Sex: Male
OW
Obese
Cancer
MI
Nursing home
ICU on Admit
Intubation on Admit

Morbidity Age ≥ 65 Years
T2DM
Statin
T2DM x Statin
Race: White
Sex: Male
OW
Obese
Cancer
MI
Nursing home
ICU on Admit
Intubation on Admit
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E. Logistic Regression for Morbidity at Six Months Age < 65 Years
525 of 4261 patients (12.3 %) age < 65 years were readmitted for CAP by six
months (Table 4.8) The T2DM/statin interaction (OR = 1.07: 95% CI 0.70 – 1.64,
p = 0.78), T2DM alone (OR = 1.24: 95% CI 0.96 – 1.59, p = 0.10), statin exposure
alone (OR = 1.14: 95% CI 0.87 – 1.49, p = 0.34), and nursing home residence (OR
= 1.31: 95% CI 0.92 – 1.86, p = 0.14) did not have a significantly increased odds
for CAP rehospitalization by six months. Odds for CAP rehospitalization by six
months was significantly associated with mechanical ventilation on admission (OR
= 1.49: 95% CI 1.09 – 2.03, p = 0.01), while history of neoplastic disease (OR =
1.31: 95% CI 0.99 – 1.74, P=0.06) and a prior MI (OR = 1.32: 95% CI 0.98 – 1.77,
P = 0.07) approached significance.
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OW (OR = 0.74: 95% CI 0.57-0.95, p = 0.02) or obese (OR = 0.75: 95% CI
0.60 – 0.93, p = 0.008) was significantly protective against CAP rehospitalization
by six months, and direct admission to an ICU (OR = 0.75: 95% CI 0.55 – 1.01, p
= 0.058) had a protective effect that approached significance. Caucasian race (OR
= 0.93: 95% CI 0.76 – 1.14, p = 0.48) and male gender (OR = 0.90: 95% CI 0.74
– 1.08, p = 0.24) were not significant (Table 4.8).

F. Logistic Regression for Morbidity at Six Months Age ≥ 65 Years
756 of 5791 patients (13.1%) age ≥ 65 years were readmitted for CAP by six
months after their initial hospitalization. T2DM (OR = 1.29: 95% CI 1.02-1.63, p
= 0.04) and prior MI (OR = 1.23: 95% CI 1.00–1.50, p = 0.05) were associated with
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a significant increased odds of CAP rehospitalization by six months. Statin
exposure alone (OR = 1.07: 95% CI 0.89-1.30, p = 0.47), OW (OR = 1.03: 95% CI
0.86-1.25, p = 0.73), a history of neoplastic disease (OR = 1.16: 95% CI 0.95–
1.42, p = 0.15), and mechanical ventilation on admission (OR = 1.10: 95% CI 0.84
– 1.43, p = 0.5) were not significantly associated with CAP rehospitalization by six
months.
OB (OR = 0.99: 95% CI 0.82-1.12, p = 0.92), the T2DM/statin interaction (OR
= 0.83: 95% CI 0.59 – 1.16, p = 0.27), Caucasian race (OR = 0.97: 95% CI 0.78 –
1.21, p = 0.80), male gender (OR = 0.99: 95% CI 0.85 – 1.16, p = 0.92), direct
admission to an ICU (OR = 0.86: 95% CI 0.67 – 1.11, p = 0.24), and nursing home
residence (OR = 0.98: 95% CI 0.79 – 1.20, p = 0.82) had a protective effect against
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CAP rehospitalization within six months but none of them were significant.
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G. Logistic Regression for Morbidity at 12 Months Overall
1634 of 10052 patients (16.3%) were readmitted for CAP by 12 months after
their initial CAP hospitalization (Table 4.9). T2DM (OR = 1.23: 95% CI 1.05-1.44,
p = 0.01), statin use (OR = 1.17: 95% CI 1.02 -1.34, p = 0.03), a history of
neoplastic disease (OR = 1.17: 95% CI 1.01-1.36, p = 0.04), and a prior MI (OR
= 1.25: 95% CI 1.07-1.45, p = 0.005), were associated with a significant increased
odds for morbidity. Mechanical ventilation on admission was also associated with
a non-significant increased odds for CAP rehospitalization by 12 months (OR =
1.13: 95% CI 0.94 – 1.37, p = 0.19). Male sex (OR = 0.88: 95% CI 0.79 – 0.98, p
= 0.024) or direct admission to an ICU (OR = 0.81: 95% CI 0.68 – 0.97, p = 0.022)
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had a significant protective effect against CAP rehospitalization by 12 months,
while Caucasian race (OR = 0.88: 95% CI 0.77 – 1.00, p = 0.058) had a protective
effect that approached significance.
The T2DM and statin interaction (OR = 0.94: 95% CI 0.75 – 1.20, p = 0.63),
OW (OR = 0.91: 95% CI 0.79 – 1.04, p = 0.15), OB (OR = 0.92: 95% CI 0.81 –
1.05, p = 0.21), age ≥ 65 years (OR = 0.995: 95% CI 0.89 – 1.12, p = 0.93), and
nursing home residence (OR = 0.92: 95% CI 0.78 – 1.09, p = 0.33) were not
significantly associated with CAP rehospitalization by 12 months.
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Table 4.9. Regression Equation for CAP Rehospitalization by 12 Months
Variables in Equation

OR

SE

p

95% CI
Lower

Higher

Overall Morbidity
T2DM
Statin
T2DM x Statin
Race: White
Sex: Male
Age ≥ 65
OW
Obese
Cancer
MI
Nursing home
ICU on Admit
Intubation on Admit
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1.23
1.17
0.94
0.88
0.88
0.99
0.91
0.92
1.18
1.25
0.92
0.81
1.13

0.08
0.07
0.12
0.07
0.06
0.06
0.07
0.07
0.08
0.08
0.09
0.09
0.10

0.01
0.03
0.63
0.06
0.02
0.93
0.15
0.21
0.04
0.01
0.33
0.02
0.19

1.05
1.02
0.75
0.77
0.79
0.89
0.79
0.81
1.01
1.07
0.94
0.78
0.94

1.44
1.34
1.20
1.00
0.98
1.12
1.04
1.05
1.36
1.45
1.37
1.09
1.37

1.24
1.18
1.14
0.85
0.80
0.77
0.77
1.21
1.30
1.28
0.80
1.24

0.12
0.12
0.20
0.09
0.09
0.12
0.10
0.13
0.14
0.17
0.14
0.15

0.06
0.18
0.51
0.06
0.01
0.02
0.01
0.15
0.06
0.14
0.11
0.15

0.99
0.93
0.78
0.71
0.68
0.61
0.63
0.93
0.99
0.93
0.61
0.93

1.56
1.50
1.67
1.01
0.95
0.96
0.93
1.57
1.70
1.77
1.05
1.65

1.21
1.13
0.86
0.92
0.95
0.99
1.05
1.14
1.22
0.83
0.81
1.06

0.11
0.09
0.16
0.10
0.07
0.09
0.09
0.09
0.09
0.10
0.12
0.13

0.08
0.18
0.34
0.39
0.45
0.99
0.55
0.16
0.04
0.07
0.07
0.67

0.98
0.95
0.63
0.76
0.82
0.84
0.89
0.95
1.01
0.68
0.64
0.82

1.51
1.34
1.17
1.12
1.09
1.19
1.25
1.37
1.46
1.01
1.02
1.35

Morbidity Age < 65 Years
T2DM
Statin
T2DM x Statin
Race: White
Sex: Male
OW
Obese
Cancer
MI
Nursing home
ICU on Admit
Intubation on Admit

Morbidity Age ≥ 65 Years
T2DM
Statin
T2DM x Statin
Race: White
Sex: Male
OW
Obese
Cancer
MI
Nursing home
ICU on Admit
Intubation on Admit
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H. Logistic Regression for Morbidity at 12 Months Age < 65 Years
682 of 4261 patients age < 65 years old (16%) were rehospitalized for CAP by
12 months (Table 4.9). T2DM (OR = 1.24: 95% CI 0.99 – 1.60, p = 0.06) and prior
MI (OR

= 1.30: 95% CI 0.99– 1.70, p = 0.06) were associated with CAP

rehospitalization by 12 months, and both approached significance. OW (OR = 0.77:
95% CI 0.61-0.96, p = 0.02), OB (OR = 0.77: 95% CI 0.63-0.93 p = 0.01), and
male (OR = 0.80: 95% CI 0.68 - 0.95, p = 0.01) were significantly protective
against rehospitalization by 12 months. Caucasian race (OR = 0.85: 95% CI 0.71
– 1.01, p = 0.06) was suggestive of a protective effect as it approached significance.
Statin use (OR = 1.18: 95% CI 0.93 – 1.50, p = 0.18), the T2DM/statin
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interaction (OR = 1.14: 95% CI 0.78 – 1.67, p = 0.51), a history of neoplastic
disease (OR = 1.21: 95% CI 0.93 – 1.57, p = 0.15), mechanical ventilation on
admission (OR = 1.24: 95% CI 0.93 – 1.65, p = 0.15) and nursing home residence
(OR = 1.28: 95% CI 0.93 – 1.78, p = 0.14) were not significantly associated with
an increased odds of CAP rehospitalization by 12 months. Direct admission to an
ICU was associated with a non-significant decreased odds for CAP
rehospitalization by 12 months (OR = 0.80: 95% CI 0.61 - 1.05, p = 0.11).

I. Logistic Regression for Morbidity at 12 Months Age ≥ 65 Years
952 of 5791 patients age ≥ 65 years (16.4%) were readmitted for CAP by 12
months after their initial CAP hospitalization (Table 4.9). CAP rehospitalization by
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12 months was significantly associated with prior MI (OR = 1.22: 95% CI 1.01 –
1.46, p = 0.04) and T2DM approached significance (OR = 1.21: 95% CI 0.98-1.51,
p = 0.08). Both direct admission to an ICU (OR = 0.81: 95% CI 0.64 – 1.02, p=
0.07) and nursing home residence (OR = 0.83: 95% CI 0.68 – 1.01, p = 0.065) were
not significantly protective against CAP rehospitalization by 12 months but
approached significance. CAP rehospitalization by 12 months was not significantly
associated with the T2DM/statin interaction (OR = 0.86: 95% CI 0.63 – 1.17, p =
0.34), OW (OR = 0.99: 95% CI 0.84 – 1.19, p = 0.99), male gender (OR = 0.95:
95% CI 0.82 – 1.09, p = 0.45), and Caucasian race (OR = 0.92: 95% CI 0.76 –
1.12, p = 0.4).
Statin use (OR = 1.13: 95% CI 0.95-1.34, p = 0.18), OB (OR = 1.05: 95% CI
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0.89-1.25, p = 0.55), a history of neoplastic disease (OR = 1.14: 95% CI 0.95 –
1.37, p = 0.16), and mechanical ventilation on admission (OR = 1.06: 95% CI 0.82
– 1.35, p = 0.67) were not statistically significantly associated with an increased
odds for CAP rehospitalization by 12 months.

J. Summary of the Regression Analysis for Morbidity Outcomes
Binary regression analyses of morbidity outcomes found a significant
protective effect against rehospitalization by one, six, and 12 months in OW and
OB patients age < 65 but not among those age ≥ 65. These findings agree with the
decision tree analyses that indicated the risk for rehospitalization increased with
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age, although the results from decision trees at one, six, and 12 months were not
significant (p > 0.05).
T2DM was associated with a significantly increased odds for CAP
rehospitalization at one month and six months for all patients and for those aged ≥
65 years. In addition, T2DM was associated with an increased odds for CAP
rehospitalization by 12 months for all patients that approached significance, as was
also found in the decision tree analyses. Statin use was associated with a
significantly increased odds for CAP rehospitalization by 12 months for all patients,
but was not significant at one month or six months.
The T2DM and statin interaction was associated with a significantly decreased
odds for CAP rehospitalization by one month in patients age ≥ 65, but this effect
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not significant for CAP rehospitalization six months or 12 months.
MI was associated with an increased odds for rehospitalization by one, six, and
12 months. MI was a significant risk factor in patients age ≥ 65 years at one and six
months, and was a significant risk factor for CAP rehospitalization at 12 months
for patients of all ages. A history of cancer was associated with a significantly
increased odds for CAP rehospitalization by 12 months for all patients, but was not
significant when the analyses were subdivided by age. Nursing home residence and
admission to the ICU were associated with a significant decreased odds for CAP
readmission at 12 months for patients age ≥ 65 years. Male sex and Caucasian race
did not have a consistent effect on morbidity; they were only significant for a
decreased odds of rehospitalization at 12 months for patients age < 65.
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Decision tree analyses discovered a stronger association than the logistic
regression analyses between T2DM, age, and statin exposure for mortality
outcomes than for morbidity outcomes. The demographic analysis of the T2DM
cohort found high prevalence of cardiovascular diseases and increased CAP
severity on admission in this group, as shown in published literature. The effects
need to be balanced, indicating the need for matched propensity score analysis
adjusting for any potential confounding effects.

Mortality Comparison using the Methodology of Mortensen et al. (2012)
For comparative purposes, this study compared the HAPPI data set compared
to published analyses. Statin use was associated with a significant protective effect
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against mortality for CAP patients in Mortensen et al. (2012).123 In this present
study, the Mortensen et al (2012). methodology was used. Mortensen et al (2012)
matched 11,498 cases exposed to either statins, angiotensin II- receptor blockers or
angiotensin-converting enzyme inhibitors, with 11,498 non- exposed controls, all
hospitalized for CAP and their data available in the Department of Veteran Affairs
VISN 17 database. Mortensen et al (2012). Reported that prior statin use was
associated with a significantly decreased 30-day mortality (OR = 0.74; 95% CI:
0.68–0.82, p < 0.05) in patients hospitalized for CAP.
In this replication study, only patients ≥ 65 years old were included. Cases were
still defined by ongoing statin exposure. However, Mortensen did not subdivide
cases and controls by T2DM status. Instead, T2DM was included as a covariate into
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the PSM model, and several other variables included in the Mortensen model:
Caucasian race, male gender, ICU admission, current tobacco use, alcohol use, IV
drug use, prior MI, CHF, COPD, liver disease, renal disease, history of neoplastic
disease, HIV, prior usage of cardiovascular medications (aspirin, beta blockers, and
antiplatelet drugs), and prior usage of corticosteroids. In the Mortensen model, race,
gender, ICU admission, neoplastic disease and prior MI were covariates in the
replication PSM model. Other variables were dropped from the regression analysis
for lack of statistical significance.
Of the 5791 HAPPI patients ≥ 65 years old, 2010 statin-exposed cases were
matched with 2010 non-statin exposed controls using the Mortensen model.
McNemar test of mortality outcomes (Table 4.10) found a significantly decreased
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odds for one month mortality (OR = 0.80, 95% CI: 0.68 – 0.96, χ2 = 6.1, p = 0.01),
which Mortensen et al. (2012). The statin exposed cases also had a decreased odds
for six month mortality (OR = 0.87, 95% CI: 0.76 – 1.00, χ2 = 3.5, p = 0.06) which
approached significance. This aligns with the decision tree analysis for mortality at
six months in T2DM patients age ≥ 65 years and on statins (Figure 4.4). At 12
months, statin-exposed cases had a tended to have a non-significant decreased odds
for 12 month mortality compared to controls (OR = 0.91, 95% CI: 0.79 – 1.04, χ2
= 2, p = 0.15).
Given the shortcomings of the replicated Mortensen methodology, this study
went further by subdividing the CAP patients by T2DM, statin use, and age in the
PSM analysis to provide greater insight in these interactions in the CAP patients.
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Table 4.10. PSM Analysis Replicating Mortensen et al. (2012)
Outcome

MantelHaenszel OR

95% CI

McNemar
Test Statistic

p-value

0.80
0.87
0.91

0.68-0.96
0.76-1.00
0.79-1.04

6.1
3.5
2

0.01
0.06
0.15

Mortality
Death at 1 month
Death at 6 months
Death at 12 months

Propensity Score Test Analysis of Hypothesis
A. Mortality Comparison Between Matched T2DM Cases and Controls
In the PSM analysis, cases (statin exposure) were matched to the controls (no
statin exposure) in the two age groups on their respective propensity scores (i.e.,
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probabilities from logistic regression). The cases and controls were matched on
propensity scores with a match tolerance of 0.05 and controlled for the following
covariates: race, gender, OW OB, history of neoplastic disease, history of a prior
MI, direct admission to an ICU, mechanical ventilation on day of admission,
nursing home residence, and being hospitalized within the past 90 days. The
McNemar test with simple sampling bootstrapping was done to compare the
mortality rates of statin-exposed to statin-unexposed matched pairs at one, six, and
12 months.
The T2DM cohort was stratified by age (<65 years versus ≥ 65) prior to PSM
analysis, because the decision tree and regression analyses indicated different
patterns of outcomes by age cohort. Out of 2734 T2DM patients, 1138 (41.6%)
were age < 65 years (41.6%) and 1596 (58.4%) were age ≥ 65 years. 754 out of
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1138 T2DM patients were matched in the age < 65 group (66.3%) while 1354 out
of 1596 T2DM patients were matched in the age ≥ 65 group (84.8%).
The McNemar test of mortality outcomes in matched T2DM cases and controls
(Table 4.9) showed T2DM statin-exposed cases age < 65 on statins had a decreased
odds for mortality by one month (OR = 0.61, 95% CI: 0.32-1.15, χ2 = 2.22) and by
six months (OR = 0.69, 95% CI: 0.43-1.08, χ2 = 2.61) than similarly aged T2DM
non-statin exposed controls. Unlike the decision tree analysis or logistic
regressions, the propensity score results were not significant. T2DM cases age < 65
had a non-significantly decreased odds for mortality by 12 months (OR = 0.70, 95%
CI 0.46-1.06, χ2 = 2.83, p = 0.09).
The odds for mortality were not significantly different between T2DM cases
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age ≥ 65 and T2DM controls age ≥ 65 by one month (OR = 0.91, 95% CI: 0.701.34, χ2 = 0.02), six months (OR = 0.97, 95% CI: 0.76-1.24, χ2 = 0.03), and 12
months (OR = 1.07, 95% CI: 0.8-1.27, χ2 = 0.001).
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Table 4.11. PSM Analysis for Mortality Outcomes in T2DM Patients
Outcome

MantelHaenszel OR

95% CI

McNemar
Test Statistic

p-value

Death at 1 months
Death at 6 months
Death at 12 months
Mortality in Age ≥ 65 years

0.61
0.69
0.70

0.32-1.15
0.43-1.08
0.46-1.06

2.22
2.61
2.83

0.14
0.11
0.09

Death at 1 months
Death at 6 months
Death at 12 months

0.91
0.97
1.07

0.70-1.34
0.76-1.24
0.80-1.27

0.02
0.03
0.001

0.87
0.85
0.99

Mortality in Age < 65 years

B. Morbidity Comparison Between Matched T2DM Cases and Controls
The McNemar found no association of statin use with morbidity outcomes in
outcomes in matched T2DM cases and controls (Table 4.12). In patients age < 65
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years, the odds for CAP rehospitalization by one month for T2DM statin-exposed
cases was 1.18 (95% CI: 0.64-2.19, χ2 = 0.19, p = 0.67) compared to T2DM nonstatin controls. A non-significant increased odds for CAP rehospitalization was
found for six months (OR = 1.13, 95% CI: 0.74-1.71, χ2 = 0.25, p = 0.62) and 12
months (OR = 1.35, 95% CI: 0.91-1.91, χ2 = 2.05, p = 0.15), post-hospitalization,
respectively.
In patients age ≥ 65, the odds for CAP rehospitalization within one month for
T2DM cases was not significant. (OR = 0.69, 95% CI: 0.42-1.11, χ2 = 2.22, p =
0.14). CAP rehospitalization was not significantly increased in frequency at six
months (OR = 0.86, 95% CI: 0.63-1.17, χ2 = 0.84, p = 0.36) or 12 months (OR =
0.91, 95% CI: 0.69-1.22, χ2 = 0.32, p = 0.57). These findings of a non-significant
increased odds for morbidity outcomes on in T2DM cases < 65 years and a non90

significant decreased odds for morbidity outcomes in T2DM cases ≥ 65 concur with
the regression analyses previously discussed in this chapter.

Table 4.12. PSM Analysis for Morbidity Outcomes in T2DM Patients
Outcome

MantelHaenszel OR

95% CI

McNemar
Test Statistic

p-value

Rehospitalization within 1 mo. 1.18
Rehospitalization within 6 mo. 1.13
Rehospitalization within 12 mo. 1.35
Morbidity in Age ≥ 65 years

0.64-2.19
0.74-1.71
0.91-1.91

0.19
0.25
2.05

0.67
0.62
0.15

Rehospitalization within 1 mo. 0.69
Rehospitalization within 6 mo. 0.86
Rehospitalization within 12 mo. 0.91

0.42-1.11
0.63-1.17
0.69-1.22

2.22
0.84
0.32

0.14
0.36
0.57

Morbidity in Age < 65 years
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C. Mortality Comparison Between Matched Non-T2DM Cases and Controls
The non-T2DM cohort was stratified by age (<65 years versus ≥ 65). Out of the
7318 non-T2DM patients, 3123 (42.7%) were age < 65 years and 4195 (57.3%)
were age ≥ 65. As in the T2DM cohort, the PSM analysis matched statin-exposed
cases to statin-unexposed controls on the propensity score that controlled for race,
gender, OW, OB, history of neoplastic disease, history of a prior MI, direct
admission to an ICU, mechanical ventilation on day of admission, nursing home
residence, and being hospitalized within the past 90 days. 1218 out of 3123 patients
were matched on propensity scores in the age < 65 group (39%) and 3082 out of
4195 patients were matched in the age ≥ 65 group (73.5%).
The McNemar test of mortality outcomes in matched non-T2DM cases and
controls (Table 4.13) showed cases age < 65 had a non-significant increased odds
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for mortality by one month (OR = 1.19, 95% CI: 0.72-1.99, χ2 = 0.36, p = 0.55)
compared to non-statin exposed controls, similar to the result in the decision tree
analysis. By PSM analysis, cases age < 65 had a non-significantly increased odds
for mortality by six months (OR = 1.29, 95% CI: 0.91-1.84, χ2 = 1.90, p = 0.17),
that may indicate a tendency. The decision tree analysis also found an increased
odds for mortality by six months in non-T2DM cases < 65 years that approached
significance. PSM analysis showed a non-significant increased odds for mortality
by 12 months in non-T2DM cases < 65 years (OR = 1.22, 95% CI: 0.89-1.67, χ2 =
1.48, p = 0.22), whereas in the decision tree analysis, non-T2DM cases age < 65
had a significant increased odds for mortality by 12 months (Figure 4.5, OR = 1.24,
95% CI 1.0-1.55, p = 0.05).
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For non-T2DM statin-exposed cases age ≥ 65 years, the PSM results found the
risk of mortality by one month (OR = 0.86, 95% CI: 0.91-1.84, χ2 = 1.48, p = 0.22)
was non-significantly decreased compared to non-T2DM controls. However, the
decision tree analysis found a decreased odds for mortality by one month in nonT2DM statin-exposed cases was significant (Figure 4.3, OR = 0.75, 95% CI 0.63 0.89, p = 0.001). PSM analysis also found a non-significant decreased odds for
mortality by six months (OR = 0.98, 95% CI: 0.83-1.16, χ2 = 0.04, p = 0.83), but
the decision tree analysis had found a significantly decreased odds for mortality by
six months in non-T2DM statin-exposed cases (Figure 4.4, OR = 0.82, 95% CI 0.71
- 0.94, p = 0.005). PSM results found non-T2DM statin-exposed cases had a nonsignificant increased odds for mortality by 12 months (OR = 1.04, 95% CI: 0.891.22, χ2 = 0.26, p = 0.61). This finding was different from the decision tree analysis,
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which found a significantly decreased odds for mortality by 12 months in nonT2DM cases (Figure 4.5, OR = 0.85, 95% CI 0.74 – 0.96, p = 0.01).

Table 4.13. PSM Analysis for Mortality Outcomes in Non-T2DM Patients
Outcome

MantelHaenszel OR

95% CI

McNemar
Test Statistic

p-value

Death at 1 months
Death at 6 months
Death at 12 months
Mortality in Age ≥ 65 years

1.19
1.29
1.22

0.72-1.99
0.91-1.84
0.89-1.67

0.36
1.90
1.48

0.55
0.17
0.22

Death at 1 months
Death at 6 months
Death at 12 months

0.86
0.98
1.04

0.70-1.06
0.83-1.16
0.89-1.22

1.90
0.04
0.26

0.17
0.83
0.61

Mortality in Age < 65 years
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D. Morbidity Comparison Between Matched Non-T2DM Cases and Controls
McNemar test of morbidity outcomes in matched non-T2DM statin-exposed
cases and statin-unexposed controls (Table 4.14) in patients age < 65 years found
non-T2DM cases had a non-significant protective effect for CAP rehospitalization
by one month (OR = 0.83, 95% CI: 0.50-1.39, χ2 = 0.38, p = 0.54), by six months
(OR = 0.96, 95% CI: 0.67-1.37, χ2 = 0.03, p = 0.86), and by 12 months (OR = 0.85,
95% CI: 0.62-1.19, χ2 = 0.77, p = 0.38), respectively.
Among non-T2DM patients age ≥ 65, the risk for CAP rehospitalization for
T2DM cases was statistically non-significant at one month, (OR = 0.69, 95% CI:
0.42-1.11, χ2 = 2.22, p = 0.14), at six months (OR = 0.86, 95% CI: 0.63-1.17, χ2 =
0.84, p = 0.36), and by 12 months (OR = 0.91, 95% CI: 0.69-1.22, χ2 = 0.32, p =
0.57), respectively. These PSM results reflect what had been previously explored
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in the regression analysis (a non-significant increased odds for morbidity outcomes
in T2DM cases age < 65 years and a non-significant decreased odds for morbidity
outcomes in T2DM cases age ≥ 65).

Table 4.14. PSM Analysis for Morbidity Outcomes in Non-T2DM Patients
Outcome

MantelHaenszel OR

95% CI

McNemar
Test Statistic

p-value

Rehospitalization within 1 mo. 0.83
Rehospitalization within 6 mo. 0.96
Rehospitalization within 12 mo. 0.85
Morbidity in Age ≥ 65 years

0.50-1.39
0.67-1.37
0.62-1.19

0.38
0.03
0.77

0.54
0.86
0.38

Rehospitalization within 1 mo. 0.86
Rehospitalization within 6 mo. 0.86
Rehospitalization within 12 mo. 0.85

0.62-1.19
0.69-1.08
0.70-1.04

0.76
1.6
2.4

0.39
0.20
0.12

Morbidity in Age < 65 years
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Survival Analysis
Cox proportional hazard regression and Kaplan-Meier analysis estimated and
modeled the survival and mortality as best as possible, because mortality outcomes
were only collected at three time frames (one, six, and 12 months) in the HAPPI
study. After adjusting for the propensity score analysis, survival estimates were
generated with patients stratified by T2DM status and age.
In T2DM patients age < 65, statin use was associated with a significantly (p =
0.02) lower hazard ratio (Figure 4.9) and significantly higher survival at one, six,
and 12 months (Figure 4.10). T2DM patients age ≥ 65 on statins had a nonsignificantly (p = 0.17) lower hazard ratio (Figure 4.11) and non-significantly
higher survival at one, six, and 12 months (Figure 4.12) compared to non-statin
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users.
Statin use was found to be associated with a significantly (p = 0.05) higher
hazard ratio (Figure 4.13) and increased mortality (Figure 4.14) at one, six, and 12
months in non-T2DM patients age < 65. The opposite findings were seen in nonT2DM patients ≥ 65, where statin use was associated with a significantly (p = 0.01)
higher hazard ratio (Figure 4.15) and lower mortality at one, six, and 12 months
(Figure 4.16).
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Figure 4.9. Kaplan-Meier Plot for T2DM patients age < 65 years one year after CAP

Hospitalization by Statin Exposure

Figure 4.10. Cumulative Mortality for T2DM patients age < 65 years one year after
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Figure 4.11. Kaplan-Meier Plot for T2DM patients age ≥ 65 years one year after
CAP Hospitalization by Statin Exposure
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Figure 4.12. Cumulative Mortality for T2DM patients age ≥ 65 years one year
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Figure 4.13. Kaplan-Meier Plot for non-T2DM patients age < 65 years one year

after CAP Hospitalization by Statin Exposure
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Figure 4.14. Cumulative Mortality for non-T2DM patients age < 65 years one year
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Figure 4.15. Kaplan-Meier Plot for non-T2DM patients age ≥ 65 years one year
after CAP Hospitalization by Statin Exposure
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Figure 4.16. Cumulative Mortality for non-T2DM patients age ≥ 65 years one
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Cost Analysis
The mean (± SD) length of hospital stay (LOS) for all HAPPI patients was 6.32
± 5.1. Using data from the 2014 National Readmission Database (NRD) – a part of
a family of databases developed for the Healthcare Cost and Utilization Project
(HCUP) by the Agency for Healthcare Research and Quality in the United States,
the average unadjusted cost of each episode of CAP hospitalization was $11774
(mean) ± $9501 (SD) in 2014, the year the HAPPI study began.137
Estimates for the LOS and costs (Table 4.14) show that T2DM patients age <
65 who were on statins had a shorter LOS (6.42 ± 5.21) and incurred less costs
($11960 ± 9706) than patients who were not previously on statins (LOS 6.42 ±
5.21, costs $12836 ± $10989), but this difference was not significant (p = 0.10).
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T2DM patients age ≥ 65 had the mean cost per hospitalization was not significantly
(p = 0.45) higher for patients without statin exposure ($13842 ± $11215) compared
to the patients with prior statin exposure ($12948 ± $10526). Non-T2DM patients
age ≥ 65 taking statins had a non-significant (p = 0.39) higher average cost per
hospitalization ($12091 ± $9222) than those without statins ($11774 ± $9036).
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Table 4.15. Cost Analysis

Length of hospital stay (LOS), costs for CAP patients by T2DM, age, and statin
status.
Cohort
T2DM

LOS (Days) Total Costs (Dollars) pMean ± SD
Mean ± SD
value
Age < 65

Statin
Non-Statin
Statin

6.42 ± 5.21
6.89 ± 5.85
6.95 ± 5.65

$11960 ± 9706
$12836 ± 10989
$12948 ± 10526

Non-Statin
Non-T2DM
Age < 65
Statin
Non-Statin
Age ≥ 65
Statin
Non-Statin
P-value for unpaired two-tailed unpaired t-test.

7.43 ± 6.02
5.88 ± 4.55
5.58 ± 4.71
6.49 ± 4.95
6.32 ± 4.85

$13842 ± 11215
$10954 ± 8477
$10396 ± 8775
$12091 ± 9222
$11774 ± 9036

Age ≥ 65
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0.10*
0.45
0.48
0.39

CHAPTER 5
DISCUSSION

A summary of the primary outcome analysis (mortality) results is listed in
Figure 5.1 and the results from the secondary outcome analysis (morbidity) is listed
in Figure 5.2.
The decision tree analysis, logistic regression analysis, and survival analysis
indicate that the T2DM and statin interaction in patients age < 65 years hospitalized
for CAP was significantly associated with a decreased odds in one, six, and all102

cause 12 month mortality. However, these protective effects were not significant
after matched propensity score analysis. The logistic regression analysis and PSM
analysis showed no significant difference in mortality odds between T2DM patients
≥ 65 years with statins use and those without statin use. The decision tree analysis
and survival analysis suggest that T2DM patients ≥ 65 years on statins have a nonsignificant decreased odds for overall mortality compared to non-statin users
(Figure 5.1).
Among non-T2DM patients hospitalized for CAP, the decision tree analysis,
logistic regression analysis, and survival analysis found statin users ≥ 65 years had
a significantly decreased odds for one, six, and 12 month mortality. In contrast,
statin users < 65 years had a significantly increased odds for mortality compared to
non-statin users. However, these effects were not significant after PSM analysis
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(Figure 5.1). As was found for the T2DM group, this implies that mortality
differences were due to covariate effects (i.e., the variables used in the propensity
score), and not due to an effect from statins.
The decision tree analysis, logistic regression analysis, and PSM analysis also
did not find a significant difference in one, six, and 12 month CAP readmission
rates between statin and non-statin users in T2DM patients age < 65. However, the
odds of rehospitalization at one, six, and 12 months for T2DM patients age ≥ 65
year were non-significantly decreased compared to non-T2DM patients (Figure
5.2). Lastly, the cost analysis demonstrated that statin use was associated with a
non-significant decreased LOS and less incurred cost of CAP hospitalization for
T2DM patients, in both age groups.
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This present investigation’s results do not agree with prior published analyses
of statin exposure and CAP in a series of papers by Mortensen.123,133,138-140
Mortensen et al. (2005A, 2005B, 2006, 2008, and 2012) used large EMR databases
to conduct retrospective observational studies with PSM to compare CAP outcomes
in patients on statins versus those not on statins. A direct comparison of the HAPPI
data to the data sets used by Mortensen et al. (2012) was made using PSM analysis
methodology. Multiple covariates were dropped from this study during the logistic
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Figure 5.1. Summary of Results for Mortality Analysis
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Figure 5.2. Summary of Results for Morbidity Analysis.
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regression analysis (i.e., current tobacco use, alcohol use, IV drug use, CHF,
COPD, chronic kidney disease, HIV and T2DM) but were included in the
propensity score replicating Mortensen et al. (2012) as analyses. The covariates I
used in the PSM analysis (i.e., race, gender, OW OB, history of neoplastic disease,
prior MI, direct admission to an ICU, mechanical ventilation on day of admission,
nursing home residence, and being hospitalized within the past 90 days) were also
included in the Mortensen replication. Mortensen’s data was restricted to patients
age ≥ 65 years. Using this methodology, the present study found a significant
decreased odds for 1 month mortality among statin users in the HAPPI study (OR
= 0.74; 95% CI: 0.68–0.82, p < 0.05), similar to Mortensen (2012), and a decreased
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odds for 6 month mortality that approached significance (OR = 0.87, 95% CI: 0.76
– 1.00, χ2 = 3.5, p = 0.06).
Analysis of the HAPPI data into four sub-groups stratified by age ( < 65 years
and ≥ 65 years) and T2DM status reduced the sample size as well as statistical
power. The entire HAPPI dataset, the non-T2DM subgroup ≥ 65 years, and the nonT2DM subgroup < 65 years had 100% statistical power, calculated by power
analysis after the PSM analysis. But the power of the T2DM subgroup < 65 years
was 80%, and the power of the T2DM subgroup ≥ 65 years was 40%. Low
statistical power decreases the chances of detecting a true effect and its
reproducibility, making the chances of finding an effect that is genuinely true are
low.141 Low power also negatively affects the likelihood that a statistically
significant finding is a true effect, or a Type II statistical error. In this present study,
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the null hypothesis was not rejected for the primary and secondary outcomes, which
indicates a probable Type II statistical error, a false negative.142
Using the Mortensen methodology, the power of the PSM analysis was 1.0.
However, the tradeoff in dividing the CAP patients by T2DM and age group in the
present results are more granular than the analyses by Mortensen and his team.123,143
Using the subgroup analyses controlled for T2DM and age heterogeneity in the
cohorts rather than adding those covariates (i.e., T2DM, age) into the PSM analysis.
The results show the granular details of how T2DM and age interact with statin
exposure in these CAP patients, focusing on outcomes in homogenous groups
which was lacking in Mortensen’s previous results. Should a follow up study have
a larger sample size to enhance the statistical power, then the subdivisions of the
107

CAP patients by age group and T2DM status may exhibit a more pronounced and
statistically significant effect because of homogeneity of within group variance by
age group and T2DM.
The PSM analysis with McNemar test for matched data detected statin use was
associated with non-significant odds for 1-month mortality (p = 0.14 and p = 0.87),
6-month mortality (p = 0.11 and p = 0.85), and 12-month mortality (p = 0.09 and
p = 0.99) in T2DM patients < 65 years and ≥ 65 years, respectively. This suggests
that T2DM patients < 65 may be the cohort most likely to benefit from the
pleotropic effects of statins on anti-inflammation. A significant effect at 12-month
mortality may be seen with higher statistical power (i.e., larger sample size).
This study’s results were more in agreement with a smaller-scale observational
study done in five different hospitals in Chicago, Illinois and Nashville, Tennessee.
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Havers et al. (2016) used PSM to match statin users and non-statin users based on
age, race, gender, education, chronic pulmonary disease, CAD, liver disease, renal
disease, T2DM, OB, smoking history, home oxygen use, ACE-I use, and influenza
vaccination, among patients hospitalized for CAP. They found no significant
association with statin use, length of stay or in-house mortality, or in-patient costs.
However, Havers et al. (2016) did not divide patients by T2DM status and did
follow up with patient outcomes after discharge.127
Figure 4.1 shows that the HAPPI study patients study skewed significantly
older than the total population of Louisville, with significantly higher proportions
in age group 65-74 years, 75-84 years, and ≥ 85 years. This finding is similar to
published CAP literature where the risk of worse outcomes increases with age.
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Compared to the non-T2DM patients, the T2DM patients were significantly more
likely to have cardiac and renal comorbidities, be on cardiovascular drug treatment,
and were more likely to be admitted directly to the ICU. Previously published
literature indicated T2DM is associated with increased CVD risk and higher
severity of CAP hospitalization. Controlling for these variables in the PSM analysis
may explain the decreased effect of statin use on mortality and morbidity, as
ASCVD also worsens with CAP outcomes.91 The percent of patients age ≥ 85 was
significantly higher in non-T2DM patients than in T2DM, indicating that fewer
patients with T2DM survive to 85 years old in the HAPPI study, as T2DM is
associated with decreased life expectancies.144
Thus, the T2DM patients hospitalized for CAP in this study may have
comorbidities that blunt any anti-inflammatory effect of statins. Comparatively,
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non-T2DM patients age < 65 years with statins had worse mortality outcomes by
logistic regression and survival analysis than those not on statins. This suggests that
even among the non-T2DM patients, earlier onset of DLP and ASCVD indicates
greater comorbidity disease burdens.
The T2DM subgroups were comprised of significantly higher proportions of
African Americans than the non-T2DM subgroups (Table 4.1). Non-Hispanic
African Americans have been shown to have one of the highest prevalence rates of
T2DM among demographic groups, second only to Hispanics.145-147 Additionally,
CAP hospitalization is apparently higher for non-Hispanic African Americans than
other racial ethnicities.148,149 The initial HAPPI study used geospatial epidemiology
to map the home addresses of the CAP patients and found that Louisville areas with
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a high CAP incidence are zip codes with a high proportion of impoverished
individuals and African Americans. The specific neighborhoods with higher-thanaverage CAP rates include Smoketown, West Louisville, Russell, and Portland.
However, the incidence of CAP among whites and African Americans in Louisville
were similar, and black ethnicity was not a significant risk factor for mortality or
rehospitalization according to the analyses conducted in this study. Socioeconomic
and environmental disparities (e.g., poor air quality, poor nutrition, suboptimal
housing conditions, limited healthcare access) are more influential determinants of
T2DM and CAP in Louisville than race inequalities. Racial and socioeconomic
disparities may increase the risk of CAP and T2DM,150-154 but further study is
needed to better delineate the role of health inequities in T2DM and CAP.
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Nursing home residence was one of the few variables in the logistic regression
analysis associated with an increased odds for CAP hospital readmission that
approached significance (p = 0.07) in patients ≥ 65. Nursing home residents may
be particularly susceptible to infectious diseases because of proximity to other
residents. The general health and advanced age of nursing home residents, and their
interaction with medical staff are opportunities for infection. If the present study
were able to track patients for more than one year, a pattern of CAP hospital
readmission and an increase in mortality may be observed.
Results in the logistic regression analysis found that OB and OW were
associated with a decreased odds for mortality at all three time points, and a
decreased odds for rehospitalization in patients age < 65 years with high BMIs.
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This finding aligns with various studies that have described a phenomenon referred
to as the “OB paradox.” Although increased BMI correlates positively with the risk
for developing T2DM and ASCVD, OW or obese subjects may have better
prognosis when compared to those with BMI of < 25. The OB paradox was reported
in ASCVD, T2DM, and in CAP, where the survival rates improve with an elevated
survival.9,10,155,156 Hypothesized explanations for the obesity paradox include
reverse causality (thinner patients are sicker than obese patients) and the potential
for adipose tissue to be protective during acute severe illnesses, when caloric intake
is inhibited.
With the ongoing COVID-19 pandemic, these results give credence to examine
the health policy recommendation of statins as an adjunctive therapy for CAP. The
American College of Cardiology guidelines recommend statins for T2DM adults
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age 40-75 years old for reduced risk of ASCVD mortality, however these agents
still remain underused.157 Among the T2DM patients in the HAPPI study, less than
a majority (46.3%) were reported to be on statins, and 52.9% of T2DM patients age
≥ 65 were on statins. This is consistent with previously reported literature, where
usage of statins in T2DM patients to be in the 40-50% range, with lower rates of
underusage in minority populations.158 This study’s findings, if validated, could
strengthen policy recommendations for prophylactic statin administration in
populations most at-risk for CAP (i.e. T2DM, age ≥ 65).
Another health policy recommendation to emerge from this dissertation would
be the replication of a large-scale epidemiological study similar to HAPPI, to
conduct research on the impact of COVID-19. The University of Louisville
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Division of Infectious Diseases created its own large-scale database and transposed
patient data from multiple healthcare EMR systems in order to better analyze the
Louisville population at large. Further health policies could enable and facilitate
the creation of similar large-scale data collection of COVID-19 in other cities or
metropolitan areas through interoperable EMR and common registries.
This would help analyze and disseminate data more efficiently and have a more
complete epidemiological picture of CAP health burden, rather than the data be
compartmentalized by different healthcare systems. It could also identify beneficial
interventions against COVID-19 that can inform future evidence-based policy
making in each region or state.
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Limitations
Several limitations exist in both the University of Louisville Pneumonia study
and this present secondary analysis of the HAPPI data. As mentioned above, low
statistical power is a primary limitation of the present investigation. The HAPPI
study did not recruit CAP patients based on statin status. Thus, matching cases and
controls was imperfect, and limited the sample size. T2DM patients could have
been analyzed by glycemic control, but again the sample size would have been too
small to analyze statin cases and controls with acceptable power. Sample size
calculation is not straightforward in a prospective observational study as this. It is
not expected to find a matching control for all statin controlled case patients, and
this is a drawback of PSM. Although PSM reduces the treatment assignment bias,
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it is very sensitive and usually requires large sample sizes. As seen here, the use of
PSM for subgroup analyses lost a large number of observations and meant any
effect in the unmatched patients went unrecorded. There may have also been an
imbalance of the covariates in subdividing the groups.
Exclusions of patients from the HAPPI study included: (1) those who did not
have a permanent or valid address in the Louisville, Kentucky area based on the US
Census Bureau data, (2) without a valid Social Security Number, or (3) were
incarcerated in a corrections system or mental health facility at the time of hospital
admission limits the generalizability of this study to the U.S. population overall.
The most famous limitation of the propensity score is the inability to account
for unobserved variables that affect assignment to treatment and outcome in the
matching procedure. The uncertainty of T2DM diagnosis and statin use are another
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issue. The “unobserved” variables are unknowns that may bias the analyses. The
decision tree and logistic regression analyses were done to identify covariates
available in the HAPPI study that significantly correlated with T2DM, statin
exposure and CAP outcomes. The PSM analysis use these covariates to conduct the
final effect balancing during matching. It is very possible that unknown variables
were not recorded by the HAPPI study that may have biased the PSM procedure.
Another limitation of this study, and implicitly the HAPPI study, is the method
of data collection via EMR records. One example is statin use, which was obtained
through medical records via ICD coding and prescription lists. No patient
interaction was attempted to ascertain the true statin status or the specific statin
used by the patient. CAP patients listed in EMR with prior statin use could have
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misreported compliance or stopped statin use after their CAP hospitalization. This
would have biased outcome follow-up, and possibly affect long-term outcomes.
These are unknown confounders that may affect analyses.
HAPPI was a multi-center observational study that used laboratory values
analyzed by different healthcare system laboratories. Samples drawn for CAP
patients on admission may vary as each of the nine hospitals may have had their
own protocols. Between-group differences may have been seen in patients admitted
to one hospital may have had a more complete workup compared to another
hospital. One of the challenges in conducting this study was blood glucose was
drawn without respect for fasting status for almost every CAP patient. HbA1c was
not regularly done, even for every diabetic patient. The HAPPI study had 3301
(32.8%) patients reported to have T2DM according to their EMR, but only 2734
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had a confirmatory HbA1c. Apparently, HbA1c was only tested on admission for
CAP patients with a history of T2DM or suspected of having T2DM. Outcomes in
prediabetics versus patients with T2DM could not be tested with a low sample size.
A possible large number of undiagnosed or underdiagnosed diabetics could have
been categorized as non-T2DM in the HAPPI study because no HbA1c was ordered
or recorded in the EMR.
Furthermore, there were many laboratory values and past medical history data
missing from the HAPPI dataset that may have been valuable to explore.
Inflammatory markers such as CRP was only collected in 192 (2%). Insulindependence was a variable collected in the medical history, but T1DM was not.
T1DM’s relationship to statin therapy and CAP could not be evaluated, and it is
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likely that 5-10% of those labelled as T2DM were actually T1DM. The causative
microbe was detected in only 991 of the 2734 CAP patients (36.2%). HDL and
triglycerides were collected in 2201 CAP patients (21.9%) while waist
circumference was not recorded. Therefore, it was not possible to analyze any
possible relationship between statin exposure and metabolic syndrome.
The EMR contained no information on the length of time the patient had used
statins. The HAPPI study did not record the type of statin, dosage or frequency of
use. Therefore, a dose response relationship or statin potency differences could not
be evaluated. In addition, statins may have been prescribed by either a hospitalist
or outpatient physician. The hospital EMR systems are not continuous between
outpatient and inpatient facilities, and information about the cases’ primary care
may be missing. Between-group residual variance can be large if the large numbers
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of the cases and controls see outpatient physicians whose information is not linked
to the hospital EMR.
A number of health policies proposal can be suggested from these limitations
dealing with the EMRs of different healthcare systems and data generation from
hospital admission. One health policy could allow for greater coordination of
between outpatient and inpatient EMRs, to share laboratory and clinical data
relevant to generate diagnoses such as T2DM and dyslipidemia. This same policy
recommendation could be augmented for medications listed in outpatient and
inpatient EMRs, to enable public health officials to follow dosage and scheduling
and observe a dose-response relationship. One final policy could be agreed-upon
protocols across the community or regions for data generation consistency
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regarding CAP and COVID-19, blunting some of the problems in data collection
encountered in the original HAPPI study.

Strengths
The HAPPI study was able to prospectively evaluate and attempt to enroll a
majority of CAP adult hospitalizations in the city of Louisville for three consecutive
years. HAPPI investigators were able to define the number of unique patients in
Louisville hospitalized with CAP using SSNs and home addresses from the US
Census Bureau. The HAPPI investigators defined guidelines for data collection and
verification for all patient medical history, hospitalization data, and outcomes.
The PSM analysis performed removed individuals in the control group who
were a poor match to the cases. Among other medical observational studies, PSM
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analysis reduced selection bias due to removing case control through matching.
PSM analysis improved internal validity better than stratification methods.159

Conclusions
Prior retrospective observational studies have found statin therapy might affect
mortality and morbidity outcomes in patients with T2DM and CAP. The present
study used data from the HAPPI study, a prospective cohort-based study of adult
patients hospitalized for CAP in Louisville, Kentucky. The objective of this
dissertation was to observe in real time the effect of prior statin therapy on CAP
patient outcomes at one, six, and 12 months.
Decision tree analysis, logistic regression analysis, and Cox regression analysis
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showed that the T2DM and statin interaction was significantly associated with
decreased mortality at one, six, and 12 months for T2DM patients age <65 , but not
in T2DM patients age ≥ 65. The results of PSM analysis with McNemar test
analysis, controlling for covariates including neoplastic disease, MI, OB, gender,
and race, showed non-significant association of the T2DM and statin interaction
with decreased odds for mortality at one, six, and 12 months for patients age <65.
No significant differences in CAP readmission at one, six, and 12 months were
found between T2DM patients on statins versus those not on statins. The cost
analysis found that statin therapy was associated with non-significant decreased
LOS and incurred costs for T2DM patients in both age groups.
This dissertation provides empirical evidence from decision tree analysis,
logistic regression, and survival analysis of a protective effect from mortality of
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statin therapy and may be most beneficial for T2DM patients hospitalized for CAP
age < 65 years. However, the sample size was reduced by the PSM analysis that
lowered the statistical power of the analysis. The results indicate that future
research, such as a potential randomized controlled trial, should recruit patients
using a power analysis to increase the probability of matching and retain an
adequate sample size. The possibility that statins may be used as adjunctive therapy
for CAP treatment remains a relevant public health question to explore, particularly
with the ongoing COVID-19 pandemic.
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